Differentiation and function of human Th17 cells and the role of their master regulator RORC2 in T cell polarization by Bürgler, Simone Sara
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
Differentation and Function of Human Th17 Cells and the Role
of their Master Regulator RORC2 in T Cell Polarization
Bürgler, S S
Bürgler, S S. Differentation and Function of Human Th17 Cells and the Role of their Master Regulator RORC2 in T
Cell Polarization. 2009, University of Zurich, Faculty of Science.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
University of Zurich, Faculty of Science, 2009.
Bürgler, S S. Differentation and Function of Human Th17 Cells and the Role of their Master Regulator RORC2 in T
Cell Polarization. 2009, University of Zurich, Faculty of Science.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
University of Zurich, Faculty of Science, 2009.
   
Differentiation and Function of Human Th17 Cells and the 
Role of their Master Regulator RORC2 in T Cell 
Polarization 
_______________________________________________________________ 
 
Dissertation 
 
zur 
 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
  
vorgelegt der 
 
Mathematisch-naturwissenschaftlichen Fakultät 
 
der 
 
Universität Zürich 
 
von 
 
Simone Sara Bürgler 
 
von 
 
Illgau SZ 
 
 
Promotionskomitee 
 
Prof. Dr. Roland H. Wenger (Vorsitz) 
PD Dr. Carsten B. Schmidt-Weber (Leitung der Dissertation) 
PD Dr. Günther Hofbauer 
 
Zürich, 2009 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    TABLE OF CONTENT 
 - i -   
TABLE OF CONTENTS 
 
 
 
TABLE OF CONTENTS....................................................................................................... i 
ACKNOWLEDGEMENTS.................................................................................................. iii 
SUMMARY ..........................................................................................................................iv 
ZUSAMMENFASSUNG......................................................................................................vi 
ABBREVIATIONS.............................................................................................................viii 
1 INTRODUCTION ...........................................................................................................1 
1.1 Adaptive immunity ...........................................................................................................................1 
1.1.1 Players of the adaptive immunity...............................................................................................1 
1.1.2 Activation and differentiation of Th cells..................................................................................2 
1.1.3 Th cell subsets .............................................................................................................................3 
1.1.3.1 Cross-regulation of Th cell subsets during polarization ...................................................4 
1.1.3.2 Th1 cells ...............................................................................................................................6 
1.1.3.3 Th2 cells ...............................................................................................................................6 
1.2 Treg cells.............................................................................................................................................7 
1.2.1 Function of Treg cells .................................................................................................................7 
1.2.2 Subtypes of Treg cells.................................................................................................................8 
1.2.3 The transcription factor FOXP3 .................................................................................................9 
1.2.3.1 Suppressive function of FOXP3 .........................................................................................9 
1.2.3.2 Transcriptional regulation of FOXP3...............................................................................10 
1.3 Th17 cells..........................................................................................................................................13 
1.3.1 Function of Th17 cells ..............................................................................................................13 
1.3.1.1 Effects of Th17 cell cytokines on tissue cells..................................................................14 
1.3.1.2 Th17 cells in inflammatory diseases ................................................................................15 
1.3.1.3 Th17 cells in host defense .................................................................................................16 
1.3.3 Development of Th17 cells.......................................................................................................17 
1.3.3.1 Cytokines involved in differentiation of murine Th17 cells ...........................................17 
1.3.3.2 Cytokines involved in differentiation of human Th17 cells ...........................................18 
1.3.3.3 Transcriptional control of Th17 cells ...............................................................................19 
1.3.4 The ROR-family of transcription factors.................................................................................19 
1.3.4.1 Expression and function of RORC2 .................................................................................21 
1.4 Objective...........................................................................................................................................23 
2  RESULTS.....................................................................................................................24 
2.1 Differentiation and functional analysis of human T helper 17 cells .......................................24 
2.2 RORC2 is involved in T cell polarization through interaction with the FOXP3 promoter 50 
2.3 Statement of contribution to publications...................................................................................71 
3 DISCUSSION................................................................................................................72 
3.1 Requirements for Th17 cell differentiation ................................................................................72 
3.2 Th17 cell effector mechanisms ......................................................................................................73 
                    TABLE OF CONTENT 
 - ii -   
3.3 Expression of the transcription factor RORC2 .........................................................................75 
3.4 Regulation of the foxp3 gene by RORC2 ....................................................................................75 
3.5 RORC2 binding motifs in the FOXP3 promoter .......................................................................76 
3.6 Mechanisms of RORC2-mediated FOXP3 suppression ...........................................................77 
3.7 Mechanisms regulating the balance of Treg and Th17 cell differentiation ...........................78 
3.8 Phenotype shift upon RORC2 downregulation..........................................................................79 
3.9 Conclusion........................................................................................................................................81 
4 CURRICULUM VITAE ................................................................................................82 
5  PUBLICATIONS..........................................................................................................83 
6  PRESENTATIONS ......................................................................................................84 
6.1 Presentations at Congresses ..........................................................................................................84 
6.1.1 Oral Presentations .....................................................................................................................84 
6.1.2 Poster Presentations ..................................................................................................................84 
6.2 Promotion Committee Meetings...................................................................................................85 
6.3 Progress Reports .............................................................................................................................85 
6.4 Journal Clubs ..................................................................................................................................86 
7 REFERENCES .............................................................................................................88 
 
                    ACKNOWLEDGEMENTS 
 - iii - 
ACKNOWLEDGEMENTS 
 
 
 
First I would like to thank Prof. Dr. Cezmi Akdis, director of the Swiss Institute of Allergy 
and Asthma Research (SIAF), for providing me the opportunity to conduct a PhD thesis at 
this great place, but also for helpful inputs to my research. 
 
 
I would like to thank PD. Dr. Carsten Schmidt-Weber for giving me an interesting and diverse 
project, for providing me all the help I needed and particularly for his extra efforts required to 
supervise my project over the distance. 
 
 
I express my gratitude to Prof. Dr. Roland Wenger and PD. Dr. Günther Hofbauer for 
accepting the responsibility for my PhD thesis as well as for helpful inputs during the 
committee meetings. 
 
 
I thank the former members of PD. Dr. Carsten Schmidt-Weber’s group - Claudio Bassin, 
Kerstin Siegmund, Nadia Ouaked, Beate Rückert and Pierre-Yves Mantel - for fruitful 
discussions and inputs and for providing me technical help whenever I needed it. 
 
 
I would like to express my thank to all SIAF members, particularly to Sven Klunker, Norbert 
Meyer, Mario Ziegler, Anna Schaffarzik and Maciek Chalubinski, for theoretical and practical 
help and also for the good working atmosphere and personal contacts. A special thank goes to 
Oscar Palomares for all the great scientific and non-scientific discussions. 
 
 
My personal thank goes to my parents for their mental and material support, for always 
trusting in my abilities, and for being confident that I do the right things even though I was 
not always able to explain what I’m doing and why. I also thank my brother for discussions 
about science and other things, and generally for being a brother like he is. 
 
 
Finally, I like to express my gratefulness to Matthias for his support and motivation, for 
listening to my problems and sorrows, for discussions about science and how to do science 
and for exploring together the non-scientific part of life. 
 
 
                    SUMMARY 
 - iv - 
SUMMARY 
 
 
T helper (Th) 17 cells represent a recently discovered subset of T helper cells. They are 
characterized by the secretion of mainly pro-inflammatory cytokines like TNF-α, IL-6, IL-
17A, IL-17F, IL-21, IL-22 and IL-26, and depend on the transcription factor RORC2 for their 
development. Th17 cells appear to be crucial for the defense of certain bacteria like 
Bacteroides fragilis, but also for immunity against parasites and yeast such as Toxoplasma 
gondii or Candida albicans. On the other hand, they are involved in the pathogenesis of many 
inflammatory and autoimmune disorders like rheumatoid arthritis, inflammatory bowel 
disease and psoriasis. Furthermore, Th17 seem to contribute to the inflammation in allergic 
diseases like allergic asthma and atopic dermatitis. While several studies investigated 
differentiation of Th17 cells in mice, little is known about the factors influencing 
development of human Th17 cells, despite their central role in a wide range of diseases. 
Regulatory T (Treg) cells, in contrast, are crucial to regulate duration of immune responses as 
well as to establish tolerance to self- and non-self antigens. Failure in either development or 
function of Treg cells may lead to autoimmune and allergic disorders. Treg cells require the 
transcription factor FOXP3 for both their development and function. Mutations in the foxp3 
gene impair the development of Treg cells and cause a lymphoproliferative disease known as 
immunodysregulation, polyendocrinopathy and enteropathy, X-linked syndrome (IPEX). 
However, beside their beneficial role in suppression of inappropriate or excessive immune 
responses, Treg cells can also detrimentally interfere with the important immune surveillance 
against cancer.  
Given that Th17 and Treg cells have both beneficial and adverse roles, it is crucial to balance 
their number and activity. Differentiation of naïve T cells towards a certain subset must 
therefore be tightly controlled in order to establish equilibrium between protective immune 
responses and tolerance to harmless self-antigens. A disturbed balance between inflammatory 
and regulatory T cells is often observed in patients suffering from autoimmune or allergic 
disorders. It is therefore of great interest to understand the mechanisms regulating this 
equilibrium, in order to develop drugs aiming to modulate the proportions of the different 
subsets. 
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This thesis investigates development and function of human Th17 cells and analyzes mutual 
cross-regulation of Th17 and Treg cells during T cell differentiation. Our data reveal that both 
Treg and Th17 cells depend on TGF-β for their development, while Th17 cells additionally 
require the inflammatory cytokines IL-1β, IL-6 and IL-23. TGF-β is necessary and sufficient 
to induce the transcription factor RORC2, which we find to be expressed in both subsets. 
Despite these similarities, in vitro-differentiated Th17 cells significantly differ from Treg and 
other T helper cells in their potency to induce IL-6 and IL-1β expression in primary bronchial 
epithelial cells. 
In a second part, this thesis reveals that RORC2 negatively regulates FOXP3 expression in a 
DNA-binding-dependent manner. T cells with down-regulated levels of RORC2 develop a 
Treg-like phenotype even under Th17-favoring conditions, demonstrating a role for RORC2 
in the polarization of Th17 versus Treg cells. 
Taken together, this study reveals mechanism of Th17 and Treg differentiation and provides a 
basis for the elaboration of therapies aiming to restore the balance between tolerance and 
immunity. 
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ZUSAMMENFASSUNG 
 
 
T Helfer (Th) 17 Zellen wurden kürzlich als eigenständige Untergruppe von T Helferzellen 
entdeckt. Sie sekretieren die vorwiegend entzündungsfördernden Zytokine TNF-α, IL-6, IL-
17A, IL-17F, IL-21, IL-22 und IL-26. Ihre Entwicklung und viele ihrer Funktionen werden 
durch den Transkriptionsfaktor RORC2 gesteuert. Th17 Zellen sind unentbehrlich für die 
Abwehr von gewissen Bakterien wie zum Beispiel Bacteroides fragilis, aber auch für den 
Schutz gegen Parasiten und Hefepilze wie Toxoplasma gondii und Candida albicans. Auf der 
anderen Seite können sie viele Entzündungs- und Autoimmunkrankheiten mitverursachen, 
darunter rheumatoide Arthritis, Morbus Crohn und Psoriasis. Im Weiteren scheinen Th17 
Zellen auch in allergischen Erkrankungen wie zum Beispiel in allergischem Asthma und 
atopischer Dermatitis eine Rolle zu spielen, indem sie zur Entzündung beitragen. Während 
mehrere Forschungsarbeiten über die Entwicklung von Maus-Th17 Zellen veröffentlicht 
worden sind, ist sehr wenig über die Entwicklung von menschlichen Th17 Zellen bekannt - 
trotz ihrer Schlüsselrolle in vielen Krankheiten. 
Regulatorische T (Treg) Zellen, im Gegensatz dazu, kontrollieren die Länge einer 
Immunantwort und spielen eine Rolle bei der Entwicklung von Toleranz gegenüber eigenen 
und fremden Antigenen. Eine Störung in der Ausbildung oder Funktion dieser Zellen führt 
möglicherweise zu verschiedenen Autoimmun- und Entzündungskrankeiten. Die Entwicklung 
und Funktion von Treg Zellen wird weitgehend vom Transkriptionsfaktor FOXP3 reguliert. 
Mutationen im foxp3 Gen beeinträchtigen die Entwicklung von Treg Zellen und verursachen 
eine X-chromosomal vererbte Krankheit, bekannt als Immundysregulation, 
Polyendocrinopathie und Enteropathie, (IPEX). Neben ihrer positiven Rolle in der 
Unterdrückung von übermässigen und unangemessenen Immunantworten können Treg Zellen 
dem menschlichen Körper allerdings auch schaden, indem sie die wichtige Kontrolle des 
Immunsystems unterdrücken, zum Beispiel bei der Entstehung von Krebs. 
Aufgrund der Tatsache, dass sowohl Th17 wie auch Treg Zellen einerseits unentbehrlich sind, 
andererseits aber auch Krankheiten mitverursachen können, untersteht ihre Entwicklung einer 
strengen Kontrolle. Dadurch kann das Gleichgewicht zwischen schützender Immunantwort 
und Toleranz gegenüber harmlosen Antigenen aufrecht erhalten werden. In Patienten, die an 
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Autoimmun- oder allergischen Krankheiten leiden, ist dieses Gleichgewicht zwischen 
inflammatorischen und regulatorischen Zellen häufig gestört. Es ist deshalb von grossem 
Interesse, die Mechanismen, die dieses Gleichgewicht regulieren, zu verstehen. Dieses 
Verständnis hilft, Therapien zu entwickeln, die zum Ziel haben, das Verhältnis der einzelnen 
T Zell Untergruppen zu beeinflussen. 
 
Die vorliegende Dissertation analysiert die Entwicklung und Funktion von menschlichen 
Th17 Zellen und untersucht die gegenseitige Regulation von Th17- und Treg Zellen während 
ihrer Differenzierung. Unsere Resultate zeigen, dass beide Zelltypen TGF-β brauchen, um 
sich zu entwickeln, während Th17 Zellen zusätzlich auf die inflammatorischen Zytokine IL-
1β, IL-6 und IL-23 angewiesen sind. TGF-β ist notwendig und ausreichend um die 
Expression des Transkriptionsfaktors RORC2 zu induzieren, den wir nicht nur in Th17, 
sondern auch in Treg Zellen nachweisen können. Trotz diesen Gemeinsamkeiten 
unterscheiden sich Th17 Zellen grundlegend von Treg und anderen T Helferzellen in ihrer 
Fähigkeit, primäre bronchiale Epithelzellen zur Produktion von IL-1β und IL-6 anzuregen. 
In einem zweiten Teil zeigt diese Arbeit, dass RORC2 als negativer Regulator des 
Transkriptionsfaktors FOXP3 agiert. T Zellen mit verminderter RORC2 Exprimierung 
entwickeln sich auch unter Th17-begünstigenden Bedingungen zu Treg-ähnlichen Zellen. 
Diese Beobachtung legt eine wichtige Rolle von RORC2 in der Polarisierung von T Zellen 
nahe.  
Zusammenfassend lässt sich sagen, dass die vorliegende Dissertation Mechanismen der Th17- 
und der Treg-Entwicklung beschreibt und damit eine Grundlage für die Entwicklung von 
Therapien zur Wiederherstellung des Gleichgewichts zwischen Toleranz und Immunität 
bereitstellt. 
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1 INTRODUCTION 
 
1.1 Adaptive immunity 
 
Mechanisms to defend the host against harmful microbes exist in all multicellular organisms. 
While the defense of invertebrates constitute a system called innate immunity, vertebrates 
have evolved a second, more specialized system - the adaptive immunity - , which tightly 
interacts with innate immunity.  
Both innate and adaptive immunity depend on the ability to distinguish harmless self (parts of 
the own body) and non-self (foreign substances). In a healthy organism, tolerance of self-
antigens and immunity against pathogens are well balanced. Under certain pathological 
conditions, however, this delicate equilibrium is disturbed. The lack of an efficient immune 
response can result in fatal infections. Such an immunodeficiency is observed in genetic 
diseases like severe combined immunodeficiency (SCID), or in patients infected with the 
human immunodeficiency virus (HIV) causing the acquired immunodeficiency syndrome 
(AIDS). In contrast, inappropriate responses against self can lead to autoimmune disorders 
like inflammatory bowel disease or rheumatoid arthritis. Similar malfunctions are observed in 
allergic diseases, where an excessive immune reaction is raised against a harmless antigen, 
which can have severe consequences for the allergic individual.  
While the innate immunity sets up an unspecific response to a broad range of invaders, the 
adaptive immunity responds to the challenge with a high degree of specificity. Furthermore, 
the adaptive immunity has the ability to build a memory, enabling it to respond more 
vigorously when exposed to the same microbe a second time. Specificity and memory 
therefore represent characteristic features of the adaptive immunity and are mediated by a 
group of immune cells called lymphocytes. 
 
1.1.1 Players of the adaptive immunity 
 
Lymphocytes can be divided into two major populations: B lymphocytes and T lymphocytes. 
B lymphocytes mature in the bone marrow and are responsible for the production of 
INTRODUCTION 
   
 - 2 - 
antibodies. Antibodies facilitate elimination of microorganisms by phagocytotic cells and 
activate the complement system, leading to lysis of the pathogen. Furthermore, they can also 
neutralize toxins or viral particles by coating and preventing them to bind to host cells.  
T lymphocytes also arise in the bone marrow, but mature in the thymus. There are two 
distinct T lymphocyte populations, the T cytotoxic (Tc) cells and the T helper (Th) cells, 
which can be distinguished by the expression of their characteristic surface molecules CD8 
and CD4, respectively. Tc cells can directly kill infected cells through release of molecules 
like granzymes or perforin, while Th cells are responsible for the activation of other immune 
cells by secreting cytokines. Differences in the cytokine pattern secreted by Th cells result in 
different immune responses and therefore decide about the success of the reaction.  
Th cells that leave the thymus are called naïve, as they have not yet been in contact with 
foreign antigens. Before these cells are able to stimulate other cells by cytokine secretion, 
they need to be activated and differentiated themselves.  
 
1.1.2 Activation and differentiation of Th cells 
 
Activation of Th cells is initiated by contact with antigens presented by antigen-presenting 
cells (APC). APC include macrophages, B lymphocytes and dendritic cells (DC). DC are are 
particularly important for the activation of naïve T cells, and they are specialized to capture 
and process antigenic material in the periphery and transport it to the secondary lymphoid 
organs. Pathogens taken up by a DC are processed into short peptides. Together with a major 
histocompatibility complex (MHC) molecule, these antigenic peptides then form a complex, 
which is displayed on the DC’s cell surface. The DC undergoes a maturation step and 
migrates to a lymph node, where it presents the peptide/MHC complex to naïve T cells that 
continuously recirculate through these organs. If the T cell receptor (TCR) of a naïve T cell 
specifically binds to the peptide/MHC complex, signaling cascades are induced, leading to 
activation, differentiation and proliferation of the T cell. In addition to the signals delivered 
by TCR stimulation, a second signal via costimulatory molecules displayed by the DC is 
required for a successful activation. Examples for such molecules are CD80 and CD86, which 
interact with CD28 on T cells, or ICOS-L, which binds to ICOS. Importantly, also cytokines 
secreted by DC and surrounding cells contribute to the development of the T cell and 
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modulate its functional properties. The composition of the cytokines secreted by the DC 
depends on the encountered pathogen. Therefore, DC activate naïve T cells by presenting the 
antigen together with a costimulatory signal and factors that tailor the properties of the T cells 
according to the pathogens to be defeated. Upon stimulation, the activated T cell rapidly 
divides. This process called clonal expansion gives rise to a substantial population of T cells 
all directed against the same antigen and with qualities appropriate to repel the corresponding 
pathogen. Together, these mechanisms mount an effective Th cell-mediated immune 
response. 
 
1.1.3 Th cell subsets 
 
In 1986 Mosmann and Coffman discovered that Th cells are not a uniform population, but can 
be subdivided into two groups, one making IFN-γ and the other producing IL-4 (1). The IFN-
γ-secreting subset has been termed Th1 cells, while IL-4-producing cells were named Th2 
cells. This Th1/Th2 paradigm has recently been complemented with a third effector T cell 
subset, the Th17 cells, named after their hallmark cytokine IL-17 (2, 3). In addition to these 
effector cell lineages, a population characterized by regulatory or suppressive activity, called 
Treg cells, exists (4).  
Although these subsets are marked by distinct features, some of their properties are 
overlapping, and subsets with mixed phenotypes seem to occur. Furthermore, it is likely that 
much more than three effector cell subsets exist. Accordingly, it has been proposed that a 
population of IL-9-producing T cells constitute a separate subset, called Th9 cells (5, 6). 
Furthermore, three very recent reports suggest the existence of Th22 cells, a subset secreting 
IL-22, which has previously been associated with Th17 cells (7-9). 
The differentiation towards a certain subset depends on the cytokines present in the 
microenvironment during stimulation of a naïve T cell with an antigen presented by an APC 
(Fig 1). Once differentiated, each Th population secretes a confined set of cytokines and has 
distinct functions in the immune system. Furthermore, the subsets express specific 
transcription factors that regulate their development. 
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Fig 1. Differentiation of T cell subsets. Naïve T helper cells differentiate towards distinct subsets, depending 
on the cytokines present during antigenic stimulation. The differentiation pathways are controlled by lineage 
specific transcription factors. Each subset secretes a characteristic set of cytokines and exerts specific functions.  
 
 
 
 
1.1.3.1 Cross-regulation of Th cell subsets during polarization 
 
Cytokines secreted by a certain T cell subset not only determine the effector function of the 
subset, but also act in an autocrine manner to give a positive feedback and promote 
development and expansion of the subset. Some cytokines also enhance the expression of 
their receptors and thereby increase the responsiveness of the cell. In addition, cytokines 
secreted by one subset can inhibit differentiation of other subsets. The initiated T cell 
population thus gets increasingly defined and dominant with every cell division. These 
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mechanisms of T cell polarization ensure expansion of the desired population and are crucial 
for mounting an effective immune response. 
Mutual inhibition of T cell subpopulations is also mediated by the lineages specific 
transcription factors (Fig 2). The Th1 cell transcription factor T-bet inhibits Th2 development 
by binding to their master regulator GATA-3, preventing it from activation of Th2-specific 
genes (10, 11). Likewise, GATA-3 can down-regulate STAT4, a transcription factor 
important for Th1 development (12). GATA-3 also negatively regulates FOXP3 expression 
and thereby inhibits Treg development (13). FOXP3 in turn suppresses Th17 development by 
inactivating their transcription factor RORC2 through direct interaction (14, 15). 
Transcription factor-mediated cross-inhibition of T cell subsets during differentiation is 
therefore an important mechanism of T cell polarization. 
 
 
 
                              
 
 
 
Fig 2. Th cell cross-regulation. Cytokines act in an autocrine manner to give a positive feedback on the 
development of their subset, while inhibiting differentiation of other subsets. Similarly, the lineage-specific 
transcription factors mutually inhibit their expression or function. These mechanisms ensure selective expansion 
of the initiated population. 
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1.1.3.2 Th1 cells 
 
Th1 cells require IL-12 signaling for their development. IL-12 acts via signal transducers and 
activators of transcription (STAT) 1, which up-regulates the Th1-specific transcription factor 
T-bet (16, 17). T-bet is important for the induction of IFN-γ production and enhances 
expression of IL-12Rβ2. Up-regulation of IL-12Rβ2 in turn renders the developing Th1 cell 
more responsive to IL-12, thereby promoting full Th1 differentiation.  
Th1 cells are important for the defense of intracellular pathogens such as mycobacteria and 
viruses. They exert these functions mainly by activating and recruiting other immune cells 
trough secretion of cytokines and chemokines like IFN-γ, lymphotoxin-α (LTα) and IL-2. 
IFN-γ produced by Th1 cells is important to enhance microbicidal activity of macrophages 
(18). Excessive function of Th1 cells, however, is a cause of many autoimmune and 
inflammatory disorders, as Th1 cytokines can induce severe inflammation and tissue damage. 
 
1.1.3.3 Th2 cells 
 
Th2 cells depend on IL-4 for their development (19). Signaling through STAT6, IL-4 induces 
low levels of the Th2 cell master regulator GATA-3 (20). GATA-3 auto-activates its own 
expression and induces Th2-specific cytokines like IL-4, IL-5 and IL-13 (21, 22). STAT5 is 
another important transcription factor in Th2 development, as IL-2-activated STAT5 induces 
the production of IL-4 (23). 
Secreting the cytokines IL-4, IL-5, IL-9, IL-13 and IL-25 (also known as IL-17E), Th2 cells 
are responsible for the defense of extracellular pathogens like helminths. IL-4 is important not 
only for a positive feedback on Th2 development, but also for IgE class switching in B cells 
(24). IL-5 and IL-13 play a crucial role in the recruitment of eosinophils upon helminth 
infection and in the expulsion of these parasites (25, 26). However, when disregulated, Th2 
functions can lead to allergic disorders like allergy and asthma. 
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1.2 Treg cells 
1.2.1 Function of Treg cells 
 
T cells with suppressive capacity have been described already in 1972 (27), and it now 
becomes apparent that during every adaptive immune response not only effector, but also 
regulatory T cells are activated and recruited. Induction of Treg cells appears to be important 
to control the strength and duration of the response as well as to establish tolerance to self- 
and non-self antigens. Failure in either development or function of Treg cells is often 
observed in autoimmune and inflammatory disorders, as demonstrated in many mouse 
models. For instance, Treg-depleted T cell suspensions transferred into nude mice evoke 
autoimmune disease, which can be prevented by cotransfer of a small number of Treg cells 
(28, 29). In another experiment, depletion of Treg induced inflammatory bowel disease as an 
inappropriate reaction to commensal bacteria, demonstrating a role for Treg cells in 
prevention of inflammatory diseases in response to foreign antigens (30). Treg cells isolated 
from normal mice have been shown to suppress allergy and to confer tolerance to organ grafts 
(31). In human, Treg cells play an important role in induction of specific tolerance towards 
allergens (32, 33). 
In contrast to the beneficial role of Tregs in suppression of inappropriate or excessive immune 
responses, they can detrimentally interfere with the important immune surveillance against 
cancer by inducing tumor-specific local immune tolerance (34). 
Treg cells have been shown to suppress the development, proliferation and/or activity of a 
wide range of cells, among them Th and Tc cells, natural killer (NK) cells, natural killer T 
(NKT) cells, DC, B cells, macrophages and osteoclasts (35-38). Treg cells mediate 
suppression of these effectors by a not yet defined cell-cell contact dependent mechanism, 
which either involves the immunosuppressive cytokines TGF-β and IL-10 (39-42), or is 
cytokine-independent (43-45). As an alternative, Treg cells may compete with effector T cells 
for cytokines and thereby induce deprivation-mediated apoptosis in these cells (46). Treg cells 
have also been suggested to kill other cells via granzyme B or perforin (38). Other studies 
report that Treg cells deliver inhibitory signals, either directly to T cells, or indirectly by 
downregulating costimulatory molecules on APC (38). 
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The mechanism of suppression probably depends on the location of the inflammation, but 
also on the type of Treg cells. 
 
1.2.2 Subtypes of Treg cells 
 
Several subtypes of Treg cells have been reported. Tr1 cells are characterized by the 
production of IL-10 and TGF-β. In vitro, they can be differentiated by antigen-stimulation in 
the presence of IL-10. Suppressive capacity of Tr1 cells has been demonstrated in a mouse 
model of colitis (47), and in human they play an important role in allergies and 
transplantation (48-51). Antigen-specific regulatory cells, called Th3 cells, were originally 
discovered in a mouse model of oral tolerance (52). They seem to play a suppressive role not 
only in many experimental autoimmune models, but also in human autoinflammatory diseases 
(53, 54). Th3 regulatory cells are triggered in an antigen-specific fashion but suppress in an 
antigen-non-specific fashion (55). Tr1 and Th3 cells belong to the group of induced Treg 
cells, and the role and significance of these Tregs in vivo is not well understood.  
More research has been done on natural Treg cells. This subset of regulatory cells is 
characterized by the expression of the surface molecules CD4 and CD25, and by high levels 
of forkhead box protein 3 (FOXP3), a transcription factor that plays a key role in Treg cell-
mediated suppression. Natural Treg cells develop in the thymus and are, unlike most other 
thymus-generated naïve T cells, already functionally mature before leaving the thymus. 
Evidence suggests that interaction of TCR with self-peptide-MHC on thymic stromal cells is 
important for the generation of natural Tregs. T cells in the periphery can also acquire FOXP3 
expression and suppressive capacity. This has been demonstrated by stimulating naïve T cells 
with antigen in the presence of TGF-β in vitro (4, 56, 57). Beside TGF-β, retinoic acid has 
been shown to facilitate development of Treg cells in peripheral tissues like in the gut (58-
61). However, Treg cells induced in the periphery are presumably functionally less stable than 
natural Treg, as suggested by a lower and more transient expression of FOXP3 (62, 63). 
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1.2.3 The transcription factor FOXP3 
 
FOXP3 belongs to the forkhead/winged helix transcription factor family and plays a central 
role in development and function of Treg cells. Initially, FOXP3 has been identified as a gene 
defective in scurfy mice, an X-linked mutant that is lethal in male mice (64). In scurfy mice, a 
frameshift mutation results in a product lacking the forkhead domain, leading to a non-
functional FOXP3 protein and hence to an abnormal immune homeostasis characterized by 
hyperactivation of T cells and cytokine overproduction. The importance of FOXP3 is further 
illustrated by the human genetic disease IPEX (immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked syndrome), caused by mutations in the foxp3 gene (65, 66). While 
female carriers of a mutant X-allele stay healthy, male IPEX-patients suffer from a 
lymphoproliferative disease with immunological and clinical symptoms resembling the 
symptoms of scurfy mice.  
 
1.2.3.1 Suppressive function of FOXP3 
 
The observation that disruption of FOXP3 impairs immune regulation initiated studies 
investigating the role of FOXP3 in Treg function. Retroviral gene transfer of FOXP3 has been 
found to be sufficient for the conversion of naïve T cells into a regulatory T cell phenotype 
similar to that of natural regulatory T cells (67). Furthermore, overexpression of FOXP3 
confers suppressor function on peripheral CD4+CD25- T cells (68, 69). These reports strongly 
suggest a key role for FOXP3 in the development and function of regulatory T cells. 
Despite this strong evidence, little is known about the function of FOXP3 on molecular level. 
However, FOXP3 has been reported to interact with transcription factors like nuclear factor of 
activated T cells (NFAT) or acute myeloid leukemia 1/runt-related transcription factor 1 
(AML1/RUNX1) (70, 71). As these transcription factors facilitate activation of effector T 
cells, FOXP3 might exert suppressive function by binding and thereby inhibiting the activity 
of these transcription factors. Similarly, two recent studies describe binding of FOXP3 to 
retinoic acid receptor-related orphan receptor γt (RORγt), the master regulator of Th17 cells 
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(14, 15).  Binding of FOXP3 to RORγt inhibits its transcriptional activation of the Th17 
developmental program, including production of IL-17.  
Genome-wide searches for FOXP3 target genes revealed that FOXP3 regulates approximately 
700 genes, either by binding directly to their promoters, or indirectly (72, 73). Interaction of 
FOXP3 with these genes can induce both transcriptional suppression or activation. Given this 
important role as activator and repressor of a wide range of genes, several studies investigated 
the mechanism regulating FOXP3 expression. 
 
1.2.3.2 Transcriptional regulation of FOXP3 
 
Signals downstream TCR stimulation are necessary for the induction of FOXP3. Studies from 
our lab revealed an activatory region in the proximal promoter of the foxp3 gene (74). This 
region contains binding sites for NFAT and activator protein 1 (AP-1), which contribute to 
the TCR-induced FOXP3 activation (Fig. 3). Additionally, cAMP response element-binding 
protein/activating transcription factor (CREB/ATF) has been shown to bind to an intronic 
enhancer element of the foxp3 gene, thereby promoting its transcription (75). 
However, TCR-stimulation appears not to be sufficient for high FOXP3 expression and IL-2 
seems to play a major role in providing a second signal for the induction of FOXP3 (76, 77). 
IL-2-mediated activation of the foxp3 gene is likely to be mediated by the transcription factor 
STAT5, as binding sites for STAT5 were found on the FOXP3 promoter (78). The 
importance of STAT5 is further underlined by a report identifying a patient carrying a 
homozygous mutation in the stat5b gene, which leads to impaired FOXP3 expression and 
Treg function (79). In addition to IL-2 and other cytokines of the common γ-chain family, 
TGF-β plays a central role in the induction of FOXP3 expression. The mechanism possibly 
involves signaling via the transcription factor Smad3, which has been shown to activate an 
enhancer region of the foxp3 gene (80). In addition, TGF-β decreases methylation of a CpG 
island in the first intron of the foxp3 gene, which leads to enhanced transcription (75).  
Interestingly, cytokines involved in Th1 cell development also positively regulate the foxp3 
gene. IFN-γ, for example, takes part in the induction of FOXP3 and the conversion of 
conventional T cells into Treg cells in EAE (81). Our group recently demonstrated that IL-27 
enhances TGF-β-induced FOXP3 expression in a STAT1-dependent manner (82). IL-27-
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induced STAT1 binds to the proximal promoter of FOXP3 and induces permissive histone 
acetylation leading to an increased transcription of the foxp3 gene. Beside STAT1 and 
STAT5, also STAT3 seems to positively or negatively influence FOXP3 expression (82-85).  
FOXP3 expression and Treg cell development is enhanced by the lipidic mediator retinoic 
acid (60, 86-88). Retinoic acid is a ligand for the retinoic acid receptor (RAR) that binds to 
the FOXP3 promoter and positively regulates its expression (89).  
In contrast, a suppressive role in FOXP3 regulation has been found for the Th2-specific 
transcription factor GATA-3 (13). This study performed in our laboratory revealed that IL-4-
induced GATA-3 binds to a palindromic GATA-site in the FOXP3 promoter, which leads to 
transcriptional repression. IL-4 activates also STAT6, which then binds to the FOXP3 
promoter and inhibits gene expression (89). Furthermore, FOXP3 expression is suppressed by 
the cytokines IL-1β, IL-6 and IL-21 (90-92). While IL-6 mediates its inhibitory function 
through methylation of a CpG island in the promoter (93), the mechanism by with IL-1β and 
IL-21 suppress FOXP3 expression remain to be determined.  
IL-1β, IL-6 and IL-21 are required for the development of Th17 cells. As FOXP3 inhibits 
Th17 cell development (14, 15), suppression of FOXP3 by these cytokines may be an 
important mechanism of Th17 development. 
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Fig 3. Transcriptional regulation of the foxp3 gene. TCR stimulation as well as cytokine signaling leads to 
activation of transcription factors that positively or negatively regulate transcription of FOXP3. RA: retinoic 
acid. 
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1.3 Th17 cells  
 
Analysis of various T cell clones revealed that IL-17A-producing T cells cannot be classified 
into Th1 or Th2 subsets, but rather represent a distinct cell subset (2, 3, 94, 95). Subsequently, 
this subset was described to secrete also IL-17F, IL-6, IL-21, IL-22, IL-26 and TNF-α, and 
has been termed Th17  (92, 97-99).  
 
1.3.1 Function of Th17 cells 
 
Receptors for Th17-cytokines are expressed on many non-immune cells like fibroblasts, 
epithelial cells, endothelial cells, keratinocytes or marrow stromal cells, and can be found in a 
wide range of tissues such as kidney, liver, intestine, colon, lung, pancreas and skin (100-
102). Upon stimulation with Th17-cytokines, structural cells respond with the production of 
pro-inflammatory cytokines, chemokines or metalloproteases, which leads to inflammation 
and tissue destruction (Fig 4). It becomes apparent that Th17 cells contribute to the 
inflammation of many inflammatory and autoimmune disorders by secreting cytokines that 
induce pro-inflammatory mediators in cells of the affected tissues. 
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Fig 4. Pathogenic mechanisms of Th17 cells. Cytokines produced by Th17 cells act on a wide range of tissue 
cells and stimulate these cells to produce pro-inflammatory and pro-fibrotic cytokines and chemokines. These 
mediators induce attraction and activation of neutrophils and tissue destruction. 
 
 
1.3.1.1 Effects of Th17 cell cytokines on tissue cells 
 
IL-17A was initially described as potent inducer of IL-6 and IL-8 (CXCL8) in fibroblasts 
(102, 103). Subsequently, IL-17A has been reported to induce other CXC-chemokines like 
CXCL1 (Gro-α), CXCL6, CXCL10 and CINC in different cells (104-107). Furthermore, IL-
17A has been shown to induce the colony-stimulating factors GM-CSF and G-CSF, and 
monocyte chemotactic protein (MCP)-1 in intestinal and bronchial epithelial cells (107-109). 
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The induction of chemoattractants is in accordance with a study reporting a high potential for 
IL-17A in the recruitment and activation of neutrophils (110). Tissue fibroblasts and 
bronchial epithelial cells release IL-6 and IL-11 upon stimulation with IL-17A (111). IL-17A 
seems to act also on immune cells as certain monocytes respond by secreting TNF-α and IL-
1β as well as metalloproteases (112, 113).  
IL-17F was shown to induce IL-6, IL-8, CXCL1 (Gro-α) and epithelial cell-derived 
neutrophil-activating protein (ENA)-78 (114, 115). Endothelial cells stimulated with IL-17F 
respond with increased expression of IL-2, TGF-β and monocyte chemoattractant protein 
(MPC)-1 (116). Other studies report induction of MIP-1beta/CCL4, IL-1β, G-CSF, GM-CSF 
and IFN-γ-inducible protein 10 (IP-10) (117-120). IL-22 up-regulates production of IL-10, 
acute phase reactants and anti-microbial peptides in keratinocytes and in several cell lines 
(101, 121, 122), while IL-26 has been shown to induce pro-inflammatory cytokines like TNF-
α, IL-6 and IL-8 in intestinal epithelial cell (IEC) lines (123). 
 
1.3.1.2 Th17 cells in inflammatory diseases 
 
Elevated levels of IL-17A mRNA have been found in blood and cerebrospinal fluid of 
patients with multiple sclerosis, but the role of IL-17A in this disease is not completely clear. 
Studies using the corresponding mouse model experimental autoimmune encephalomyelinitis 
(EAE) showed that Th17 cells are responsible for the inflammation in this disease (96), and 
that IL-17A and IL-22 promote blood-brain barrier disruption, kill neurons and promote 
central nervous system inflammation through lymphocyte recruitment (124). IL-17A and IL-
17F play also a role in rheumatoid arthritis (125) as well as in the corresponding mouse model 
collagen-induced arthritis (126, 127). The pathogenic mechanism seems to involve IL-17A-
mediated induction of metalloproteases and activation of osteoclasts, which leads to 
destruction of bones and cartilage (128). 
Increased levels of IL-17A are also found in biopsies from inflamed colonic tissue of 
inflammatory bowel disease patients (129). IL-17A stimulates production of matrix 
metalloproteases and pro-inflammatory cytokines in colonic subepithelial myofibroblasts 
(130) and inhibits the proliferation of intestinal epithelial cells (131), as does IL-26 (123). 
INTRODUCTION 
   
 - 16 - 
This suggests that Th17 cells not only contribute to inflammation and tissue damage in IBD, 
but also interfere with the repair mechanism important for maintenance of tissue integrity.  
Th17 cells seem to be involved in psoriasis, as increased levels of IL-17A have been found in 
psoriatic patients (132). Similarly, IL-22 mediates dermal inflammation and acanthosis and is 
required for skin inflammation in a mouse model of psoriasis (133, 134). IL-17A and IL-22 
induce anti-microbial peptides and matrix metalloproteases that are commonly found in 
psoriatic skin (97, 122). Th17 cells might therefore contribute to skin inflammation via 
induction of these mediators. Hints for a role of Th17 cells in allergic skin diseases come 
from studies describing Nickel-specific Th17 cells (135) and expression of IL-17A in acute 
lesions of atopic dermatitis patients (136). The mechanism by which Th17 cells contribute to 
these diseases needs to be determined. 
Increased levels of IL-17A have been found in patients with allergic asthma (111, 137), which 
may explain the high numbers of neutrophilic granulocytes in allergic airways (105, 138). IL-
17A has also been described to induce expression of the mucin genes MUC5AC and MUC5B, 
contributing to mucus hypersecretion (139). Besides, IL-17A might have a role in airway 
remodeling, a feature commonly observed in severe asthma, as IL-17A was shown to induce 
the pro-fibrotic cytokines IL-6 and IL-11 (140). Together, these reports suggest an 
involvement of Th17 cells in chronic inflammation in asthmatic airways, leading to 
irreversible changes.  
IL-26 seems to be present in inflamed tissue in general (141), but its role in disease is not 
clear yet and functional investigations are complicated by the fact that IL-26 does not exist in 
mice.  
Taken together, Th17 cells contribute to inflammation and tissue destruction in many 
diseases. However, Th17 cell-mediated inflammatory responses represent also an important 
defense mechanism against various pathogens. 
 
1.3.1.3 Th17 cells in host defense 
 
High induction of IL-17A has been reported in T cells after priming with lysates of Borrelia 
burgdorferi (95). Similarly, IL-17A has been shown to be necessary for protection from 
Klebsiella pneumonia infections (110), and to be important in the defense of other bacteria 
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like Bacteroides fragilis (142), and Porphyromonas gingivalis (143). In addition, IL-17A 
plays a role in the expulsion of parasites and yeasts like Toxoplasma gondii (144) or Candida 
albicans (145).  
IL-22 seems to be important for the defense of Citrobacter rodentium (146). Furthermore, IL-
22 levels increase upon infection with Mycobacterium tuberculosis and Klebsiella 
pneumoniae, suggesting a role for IL-22 in the immune response against these bacteria (147, 
148). The mechanisms of IL-17A- and IL-22-mediated host defense differ: while IL-17A 
confers immunity against pathogens by attracting neutrophils (110), IL-22 enhances the 
expression of β-Defensins, psoriasin, calgranulin A and calgranulin B in keratinocytes, 
thereby increasing their antimicrobial defense (101, 122). 
 
1.3.3 Development of Th17 cells 
1.3.3.1 Cytokines involved in differentiation of murine Th17 cells 
 
Studies reporting that IL-17-producing cells are markedly diminished in IL-23-deficient mice, 
and that these mice are resistant to EAE (96, 149) suggested a key role for IL-23 in Th17 cell 
development. However, despite the important role of IL-23 in IL-17 production, IL-23 failed 
to induce IL-17 in naïve T cells, which is not surprising, as naïve T cells do not express a 
receptor for IL-23. Subsequently, three independent reports described that a combination of 
IL-6 and TGF-β can induce IL-17 production from naïve T cells (150-152). The involvement 
of TGF-β in the development of the inflammatory subsets of Th17 cells was a surprise, as 
TGF-β has been associated mainly with anti-inflammatory effects such as the development of 
regulatory T cells. Thus, IL-6 seems to be the factor that favors Th17 cells over Treg cells in 
the presence of TGF-β. Another important role of IL-6 in the Th17 development is to induce 
expression of the receptor for IL-23, a characteristic feature of Th17 cells (153, 154). The role 
of IL-23 in Th17 cells development is still not fully clear. Although IL-23 cannot induce de 
novo differentiation of Th17 cells, there is now a consent that IL-23 is important for the 
expansion of differentiated Th17 cells and for the stabilization of their phenotype, 
characterized by sustained IL-17 production (96, 152, 154-156). Furthermore, IL-23 appears 
to be involved in the effector function of Th17 cells, as IL-23-deficient mice are unable to 
elicit a protective Th17 cells response upon infection with Citrobacter rodentium (151).  
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T cells generally require cytokines of the common gamma chain family such as IL-2 for their 
survival. Surprisingly, Th17 cells are not dependent on IL-2, but might rather be inhibited by 
IL-2 (157). IL-21, another common gamma chain family member has been suggested to act as 
a survival factor for Th17 cells and may even substitute for IL-6 (92, 154, 158). Induced by 
IL-6, IL-21 is produced by Th17 cells themselves and can act in an autocrine manner. IL-1β, 
a pro-inflammatory cytokine like IL-6 appears to contribute to the development of Th17 cells, 
although it cannot substitute for IL-6 (152, 159). 
Taken together, IL-6 and TGF-β are the key mediators to induce differentiation of naïve T 
cells towards Th17 cells in mice, a process that is enhanced by IL-1β. In addition, IL-21 and 
IL-23 seem to be important for the expansion of the population and for its functions such as 
IL-17 production. 
 
1.3.3.2 Cytokines involved in differentiation of human Th17 cells 
 
While development of mice Th17 cells has been intensively studied, the differentiation of 
human Th17 cells is still controversial. One report suggests a combination of IL-1β and IL-6 
to be optimal for Th17 induction with IL-23 having poor effects (160). In contrast, two other 
groups describe an efficient induction of human Th17 cells by IL-23 (99, 161). Apart from 
these inconsistencies, the three groups suggested that, in contrast to mouse, TGF-β is not 
necessary for human Th17 cells development. Three recent reports, however, support a 
central role for TGF-β in human Th17 cells development (162-164). The discrepancies might 
be due to differences in culture conditions, such as usage of serum. Alternatively, different 
procedures of naïve T cell isolation might result in various amounts of contaminating memory 
cells, which may influence the results.  
Similar to the observations in mice, IL-21 has been described to be involved in the 
development of human Th17 cells and is proposed to substitute for IL-6 under certain 
conditions (164).  
Therefore, human Th17 cells appear to require similar cytokines for their induction, although 
differences might exist. However, further investigations need to be conducted to elucidate the 
factors regulating human Th17 cell development. 
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1.3.3.3 Transcriptional control of Th17 cells 
 
One mechanism by which cytokines exert their functions is through activation of the STAT-
signaling pathway. In T cell differentiation, particular STAT molecules induce the lineage-
specific transcription factors T-bet, GATA3 or FOXP3. STAT3 has been reported to be a 
crucial component in the differentiation pathway of Th17 cells, as mice bearing increased 
STAT3 activity were found to have an increased IL-17 production (165). Activated by IL-23, 
STAT3 binds to the IL-17 promoter, thereby inducing its transcription. STAT3 signaling can 
also be induced by IL-6. Consistently, TGF-β- and IL-6-mediated Th17 cell differentiation is 
defective in STAT3-deficient mice (155). Moreover, STAT3 appears to be involved in the IL-
21-mediated Th17 development (92, 154). In addition to STAT3, interferon-regulatory factor 
4 (IRF4) takes part in Th17 differentiation, as IRF4-deficient mice completely lack Th17 cells 
and are protected from the Th17-mediated disease EAE (166). 
While STAT3 and IRF4 are not exclusively expressed in Th17 cells, RORC2 (also named 
RORγt) has been identified as lineage specific transcription factor of Th17 cells (153, 162, 
163). Overexpression of RORC2 promotes Th17 cell differentiation, while RORC2-deficient 
mice have an impaired Th17 response. Moreover, EAE is attenuated in these animals due to 
reduced numbers of Th17 cells. These findings strongly support a role for RORC2 as master 
regulator of Th17 cells development. However, RORC2-deficient mice still have low 
numbers of Th17 cells and can develop EAE. Recently, RORA (RORα) has been shown to 
promote Th17 cell development when overexpressed (167). Therefore, RORA might 
substitute for RORC2 in RORC2-deficient mice, which can explain the presence of Th17 
cells in these mice. 
 
1.3.4 The ROR-family of transcription factors 
 
The family of retinoic acid receptor (RAR)-related orphan receptors (ROR) consists of three 
members: RORA (NR1F1, RORα, RZRα), RORB (NF1F2, RORβ, RZRβ) and RORC 
(NF1F3, RORγ, RZRγ). Each ROR gene generates several isoforms that differ only in their 
N-termini (168-170). Four human RORA isoforms have been identified - RORA1-4 - while 
only isoform 1 and isoform 4 exist in mice.  Two RORB isoforms have been reported in mice 
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and one isoform in human. The rorc gene generates two isoforms, RORC1 and RORC2 (also 
referred to as RORγ and RORγt) in both, human and mice. Most ROR isoforms are under the 
control of different promoters and exhibit a tissue specific expression pattern. 
Proteins of the ROR family are between 459 and 556 amino acids in length and display a 
typical nuclear receptor domain structure consisting of four domains: an N-terminal domain, a 
highly conserved DNA-binding domain (DBD) consisting of two zinc finger motifs, a hinge 
domain and a C-terminal ligand-binding domain (LBD). The DBD binds to DNA containing a 
so-called ROR-response element (RORE), which consists of the core motif GGTCA preceded 
by an A/T-rich sequence (171, 172). In contrast to other nuclear receptors, ROR family 
proteins bind DNA as monomers (169, 171, 173). The interaction is mediated by the loop 
between the last two cysteines in the first zinc finger, and a 30 amino acid long region 
downstream the two zinc fingers (169, 174). Due to the high homology of the DBD between 
the ROR family members and their different isoforms, they recognize closely related RORE. 
However, the affinities for different RORE vary between members and isoforms. This is due 
to the differences in their N-terminal domains, which are involved in DNA-recognition and 
thereby confer DNA-binding specificity (169). The LBD of ROR transcription factors is 
characteristic for nuclear receptors, but contains - in addition to the typical 12 α-helices - two 
additional helices (175, 176). RORA has been described to interact with cholesterol, 7-
dehydrocholesterol and cholesterol sulfate (175, 177), while RORB and RORC have been 
found to bind several retinoids (178). However, it is not fully clear how these ligands modify 
DNA-binding capacity of ROR family members and whether ligand binding has a 
physiological relevance.  
ROR family members interact with both co-activators and co-repressors to positively or 
negatively regulate transcription of target genes (Fig. 5). Together with co-activators they 
induce histone acetylation, leading to decompaction of the chromatin and therefore to 
activation of gene transcription (179-182). Interacting with co-repressors, ROR family 
members mediate chromatin de-acetylation, which is associated with gene repression (183-
185).  
ROR family transcription factors have been described to be involved in regulation of 
circadian rhythm and behavior (186-189). RORA is critically involved in the development of 
the retina by regulating several genes in the photoreceptors (190), but also in thymopoiesis 
and lymphocyte development (191) and in the lipid metabolism (192-196). RORB seems to 
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be important in the development of the brain and the retina, as RORB-deficient mice display a 
duck-like gait and retinal degeneration (187, 197). RORC plays a key role in the development 
of lymph nodes and Peyer’s patches and in the regulation of thymopoiesis (170, 198-200). 
 
 
                                         
                 
 
 
Fig 5. Transcriptional regulation by ROR family transcription factors. ROR family members bind to 
ROREs in the regulatory region of their target genes and interact with co-activators or co-repressors. Interaction 
with co-activators induces histone acetylation, which leads to decompaction of the chromatin and therefore to 
activation of gene transcription. Through interaction with co-repressors, ROR family transcription factors 
mediate chromatin de-acetylation, which is associated with gene repression.  
 
 
1.3.4.1 Expression and function of RORC2 
 
The two isoforms of RORC display very little differences in their amino acid sequence, but 
show a completely distinct expression pattern. While RORC1 is expressed in many tissues 
like liver, adipose tissue, skeletal muscle and kidney, RORC2 is expressed only in a few 
immune cells. Mice deficient in RORC2 lack lymph nodes and Peyer’s patches, suggesting a 
crucial role for RORC2 in the development of certain lymphoid organs (199, 200). Failure in 
development of lymph nodes and Peyer’s patches is due to an absence of lymphoid tissue 
inducer cells in RORC2-deficient mice (198). These cells play a critical role in the 
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development of lymph nodes and Peyer’s patches, but also in the organogenesis of isolated 
lymphoid follicles, which are lymphoid compartments located in the intestines (201). In 
contrast, development of several other lymphoid tissues like nasal- and bronchial-associated 
lymphoid tissue (NALT and BALT) is not affected in RORC2-deficient mice, suggesting that 
development of these organs is governed by a different regulator (202). 
Several studies suggested RORC2 to play a central role in thymopoiesis by regulating 
proliferation and apoptosis in immature thymocytes (170, 171, 199, 200, 203, 204). RORC2 
positively regulates the anti-apoptotic gene Bcl-XL, thereby promoting thymocyte survival. 
Thus, RORC2-deficient mice have a significantly smaller thymus in early life, due to a 
dramatically reduced number of thymocytes.  
More recently, a role for RORC2 in T cell differentiation has been described and RORC2 is 
now accepted as key transcription factor of Th17 cells (153, 162, 163). RORC2-deficient 
mice show markedly reduced numbers of Th17 cells (153), and overexpression of RORC2 
greatly increased IL-17 production (162, 163). RORC2 has been shown to bind to two RORE 
in an enhancer element of the il17-il17f locus, suggesting that RORC2 directly activates 
expression of these Th17-specific genes (167). 
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1.4 Objective 
 
Th17 cells constitute an important part of the immune system’s host defense. If not properly 
controlled, they induce or contribute to inflammation in many autoimmune disorders as well 
as in allergy and asthma. Treg cells, in contrast, suppress excessive immune responses, but 
they can undesirably interfere with immunity against in infections or cancer. Differentiation 
of naïve T helper cells towards one of these subsets must therefore be tightly controlled to 
establish equilibrium between protective immune responses and tolerance against harmless 
(self-) antigens. Understanding the mechanisms regulating this equilibrium is of great interest 
in order to develop therapies for autoimmune diseases. 
The aim of this thesis was to gain insight into the pathways leading to the differentiation of 
Th17 cells and to analyze the mechanisms controlling the delicate balance between Th17 and 
Treg cell differentiation. 
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2  RESULTS 
 
2.1 Differentiation and functional analysis of human T helper 17 cells  
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Abstract 
Background: T helper (Th) 17 cells are of pathologic relevance in autoimmune disorders and 
presumably also in allergy and asthma. Regulatory T (Treg) cells, in contrast, suppress 
inflammatory and allergen-driven responses. Despite these disparate functions, both T cells 
subsets have been shown to be dependent on TGF-β for their development.  
Objective: The aim of the study was to analyze differentiation and function of human Th17 
cells in comparison with other T helper cell subsets. 
Methods: Naïve human CD4+ T cells were in vitro-differentiated and gene expression was 
analyzed by quantitative real-time PCR, ELISA and immunofluorescence. The function of T 
helper cell subsets was assed by monitoring the response of primary bronchial epithelial in 
co-culture experiments. 
Results: In vitro-differentiated Th17 cells differ from Treg and other T helper cells in their 
potency to induce IL-6 and IL-1β expression in primary bronchial epithelial cells. To acquire 
this functions including IL-17 production, TGF-β, IL-1β, IL-6 and IL-23 are necessary during 
Th17 cell differentiation. In contrast, TGF-β alone is necessary and sufficient to induce the 
transcription factor RORC2. This transcription factor, previously thought to be specific for 
Th17 cells, is also expressed in Treg cells, CD25+ cells, cytotoxic T cells and in natural killer T 
cells. 
Conclusion: This study demonstrates mechanisms of differentiation to human Th17 cells, a 
subset that effectively and uniquely modulate function of primary bronchial epithelial cells. 
 
Key Messages: Human Th17 cells differ from other subsets in their potency to induce 
proinflammatory cytokines in bronchial epithelial cells. The transcription factor RORC2 is 
not exclusively expressed in Th17 cells.  
 
Capsule summary: Human Th17 cells represent a functionally distinct subset that potently 
induces proinflammatory cytokines in primary bronchial epithelial cells, suggesting an 
implication in airway inflammation. 
 
Key words: Interleukin-17, regulatory T cells, differentiation, primary bronchial epithelial 
cells, airway inflammation, transcription factor, transforming growth factor β 
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 Introduction 
 
T helper cells translate antigen stimulation to tissues and instruct tissue cells to raise immune 
responses (205). The type of response depends on the properties of the T cells that interact 
with the tissue. In allergen-induced reactions, tissue cells are modulated by T helper (Th) 2 
cells, which leads to a response including eosinophilia, IgE production, mucus hypersecretion 
and airway remodeling (206). Beside Th2 cells, also Th1, regulatory T (Treg) and Th17 cells 
play a role in atopic diseases (205). Differentiation from naïve T cells towards distinct T 
helper subsets depends on the cytokine-milieu during differentiation and involves the lineage-
specific transcription factors T-bet, GATA3 and FOXP3 for Th1, Th2, and Treg cells, 
respectively. The retinoic acid receptor (RAR)-related orphan nuclear receptor gt (RORγt) has 
been shown to be necessary and sufficient for murine Th17 development (153). RORγt and its 
isoform RORγ belong to the ROR-subfamily of nuclear receptors, which also includes RORα 
and RORβ. Recently, a role for RORα in Th17 development has been described in mice 
(167). 
Each T helper cell subset secretes a characteristic set of cytokines. IL-17A is specifically 
produced by the Th17 subset and coordinates tissue inflammation through induction of pro-
inflammatory cytokines and chemokines like IL-6, TNF-α and IL-8 (207). Consistently, Th17 
cells were shown to play a key role in many autoimmune disorders, such as rheumatoid 
arthritis, multiple sclerosis, systemic lupus erythematous and inflammatory bowel disease 
(208-211). Moreover, there are studies suggesting that Th17 cells are also implicated in 
allergy and asthma (111, 212, 213). As a consequence, current research efforts attempt to 
elucidate the development and function of this pathogenic T cell population. Whereas the 
factors responsible for human Th17 cell development are still not completely clear, three 
independent studies describe a crucial role for TGF-β and IL-6 in the differentiation of murine 
Th17 cells (150-152). TNF-α and IL-1β amplify this process, while IL-23 is important for 
stabilization of already differentiated Th17 populations and for an effective pathogen defense 
(96, 214). Beside its role in the differentiation of Th17 cells, TGF-β is a crucial factor for the 
development of Treg cells. It has been shown that TGF-β converts CD4+CD25- T cells to T 
cells with a regulatory phenotype in vitro (4, 215, 216). However, the mechanisms 
downstream of TGF-β leading to such completely different T cell phenotypes are still not 
very well understood.  
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The current study investigates developmental pathways and effector function of human Th17 
cells in relation to other T cell subsets and examines the role of TGF-β and other Th17-
differentiating cytokines in these events. TGF-β is necessary and sufficient for the induction 
of the transcription factor RORC2, which we detect not only in Th17 cells but also in Treg 
cells, CD25+ cells, cytotoxic T cells and in natural killer T cells. In addition to TGF-β, also 
IL-1β, IL-6 and IL-23 are required for the differentiation of a Th17 population that potently 
induces proinflammatory cytokines in primary human bronchial epithelial cells. 
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Methods 
 
Cell isolation 
Peripheral blood mononuclear cells (PBMC) are isolated from buffy coats of healthy donors 
using Ficoll (Biochrom KG, Berlin, Germany) density gradient centrifugation. CD4+ T cells 
are purified with anti-CD4 magnetic beads and Detach-a-Bead antibodies (Dynal, Hamburg, 
Germany). CD45RA+, CD45RA-, CD14+, CD19+, CD3+CD56+, CD25-, CD25+ and CD8+ cells 
are isolated using MACS magnetic beads (Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany). For the purification of CD3+CD56+CD25-CD69- cells, CD56+ cells are isolated 
from PBMC using anti-CD56-PE antibodies (BD Bioscience, Allschwil, Switzerland) and 
anti-PE MACS magnetic beads (Miltenyi). Afterwards, CD56+ cells are stained with anti-
CD3-FITC, anti-CD25-PE-Cy5 and anti-CD69-PE-Cy5 antibodies (all Beckman Coulter, 
Krefeld, Germany) and CD3+CD56+CD25-CD69- are sorted using a FACSAria II sorting 
system (BD Bioscience). Purity is higher than 97%. 
 
Cell cultures  
All cell cultures are carried out in serum-free AIM-V medium (Life Technologies, Basel, 
Switzerland) supplemented with IL-2 (25 U/mL, Proreo Pharma AG, Liestal Switzerland). 
CD4+CD25-, CD4+CD25+, CD8+, CD3+CD56+ and CD3+CD56+CD25-CD69- cells are 
stimulated for 12 h with soluble anti-CD3 (4 µg/mL) and anti-CD28 (4 µg/mL) antibodies. 
Anti-CD3 and anti-CD28 antibodies are produced using the hybridoma cell line OKT3 
(American Type Tissue Collection, Manassas, VA, USA) and the hybridoma cell line 15E8 
(CLB, Amsterdam, The Netherlands). CD19+ cells are stimulated with soluble CD40 ligand 
(20 mg/ml, Biogen, Zug, Switzerland). CD14+ cells are stimulated with lipopolysaccharide 
(LPS, 10 ng/ml, Sigma, Buchs, Switzerland). Neutralizing anti-TGF-β antibody is purchased 
from R&D (Abingdon, UK). IL-21 is purchased from eBioscience (San Diego, USA) and 
used at a concentration of 25 ng/ml) 
 
Suppression assay 
CD4+CD45RA+ T cells are cultured under Treg condition during 10 days. At that point, 
autologous CD4+ T cells are isolated. CD4+ responder T cells are washed twice with PBS and 
labeled with 2 µM CFSE (Invitrogen, Paisley, UK) for 3 min at RT. After washing with 
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complete RPMI (Life Technologies), the cells are cultured in 96 round-bottom plates in the 
presence of anti-CD3 antibodies (4 µg/ml) during 5 days. The proliferation of CD4+ responder 
T cells is analyzed by flow cytometry. 
 
Differentiation of Th1, Th2, Treg and Th17 cells 
CD45RA+ T cells are stimulated with soluble anti-CD3 (4 µg/mL) and anti-CD28 antibodies 
(4 µg/mL). Th0 cells are generated in the presence of neutralizing anti-IL-4 antibodies (5 
µg/mL, R&D, Abingdon, UK), anti-IL-12 antibodies (25 ng/mL, R&D) and anti-IFN-γ 
antibodies (1 µg/ml, R&D). Th1 cells are differentiated in the presence of IL-12 (5 mg/ml, 
R&D) and neutralizing anti-IL-4 antibodies. Th2 cells are generated in the presence of IL-4 
(25 ng/mL, R&D) and neutralizing anti-IL-12 antibodies. Treg cells are generated, as 
previously described (13), in the presence of TGF-β (5 ng/mL, R&D), neutralizing anti-IL-12 
antibodies and neutralizing anti-IFN-γ antibodies. Th17 cells are differentiated in the presence 
of TGF-β, IL-6 (20 ng/mL, PeproTech EC, London, UK), IL-1β (10 ng/mL, PeproTech EC), 
IL-23 (10 ng/mL, eBioscience, San Diego, USA), neutralizing anti-IL-12 antibodies and 
neutralizing anti-IFN-γ antibodies. Dose titrations are performed and the optimal dose for 
each cytokine and antibody is determined in preliminary experiments.  
 
T cell coculture with NHBE cells 
Normal human bronchial epithelial (NHBE) cells (LONZA, Visp, Switzerland) are 
maintained in BEBM (LONZA) and are plated in a 24-well dish to be 90% confluent the day 
of the experiment. NHBE cells are used at passage numbers 2 or 4. T cells are differentiated 
as described above. At d 6, T cells are washed to remove the cytokines used for 
differentiation and were restimulated for 24 h with anti-CD3 and anti-CD28 antibodies. T 
cells are added to NHBE cells at a number of 5x105 cells per well, or cultured alone. 
Alternatively, the supernatants of washed and restimulated T cells are added. To block 
transcription in T cells, the T cells are incubated with Actinomycin D (10 µg/ml, Invitrogen, 
Paisley, UK) during the last hour of restimulation. To block cytokine secretion, T cells are 
incubated with Brefeldin A (10 µg/mL, Sigma, Buchs Switzerland). The T cells are washed to 
remove Actinomycin D and Brefeldin A before co-culturing. After 6 h of coculture, NHBE 
cells and T cells are harvested for mRNA analysis. Supernatants for cytokine analysis by 
ELISA and cytometric bead array are collected after 48 h. For immunofluorescence 
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microscopy, NHBE cells grown on coverslips are cocultured with T cells for 30 h. Brefeldin 
A is added during the last 3 h to block cytokine secretion. 
 
Isolation of RNA, cDNA synthesis and quantitative real-time PCR 
Total RNA is isolated using the RNeasy mini kit (Qiagen, Hombrechtikon, Switzerland) 
according to the manufacturer's protocol. Reverse transcription is performed with TaqMan 
reverse transcription reagents (Fermentas, Nunningen, Switzerland) using random hexamer 
primers according to the manufacturer's protocol. 
The PCR primers and probes are designed based on the sequences reported in GenBank with 
the Primer Express software version 1.2 (Applied Biosystems). Primers used for relative 
quantification are listed in table 1. All primers are spanning intron-exon borders and are 
verified for efficacy over a 4-log concentration range. The prepared cDNAs are amplified 
using iTaq SYBR Green Supermix with ROX (BioRad, Basel, Switzerland) according to the 
manufacturer’s recommendations in an ABI PRISM 7900 Sequence Detection System 
(Applied Biosystems). Relative quantification and calculation of the range of confidence is 
performed using the comparative ΔΔCT method. EF-1α is used as endogenous control. All 
amplifications are conducted in triplicates. 
 
Determination of cytokine concentration 
T cells are restimulated at d 7 with anti-CD3 and anti-CD28 antibodies. After 48 h, 
supernatants are collected and IL-17A and IL-6 levels are analyzed by ELISA (eBioscience 
and PeproTech EC, respectively) according to the manufacturer’s instructions. Concentrations 
of IFN-γ, IL-1β, IL-4, IL-5, IL-8, IL-13, IL-17A, G-CSF and GM-CSF are determined by 
cytometric bead array (BioRad, Reinach, Switzerland) according to the manufacturer's 
protocol. 
 
Immunofluorescence 
The cells grown on coverslips are fixed for 10 min with 1% paraformaldehyde (Fluka, Buchs, 
Switzerland) and permeabilized with detergent (0.1% Triton (Fluka), 0.02% SDS (Roth, 
Karlsruhe, Germany) in PBS (Invitrogen, Basel, Switzerland) for 5 min. Next, the cells are 
blocked in 2% BSA (Fluka) in PBS for 30 min, probed for 1 h with fluorescein isothiocyanate 
(FITC)-labeled anti-IL-6 antibodies (1:5, BioLegend, Uithoorn, The Netherlands) and again 
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fixed in 1% paraformaldehyde. After mounting using VectaShield mounting medium 
containing 4',6-Diamidino-2-phenylindol (DAPI) (Vector Laboratories, Burlingame, CA), the 
cells are analyzed with a Leica TCS SPE confocal microscope (Leica Microsystems AG, 
Glattbrugg, Switzerland). 
 
Table 1. Primers used for quantitative real-time PCR 
 
EF-1α fw CTGAACCATCCAGGCCAAAT 
EF-1α rv GCCGTGTGGCAATCCAAT  
FOXP3 fw GAAACAGCACATTCCCAGAGTTC 
FOXP3 rv ATGGCCCAGCGGATGAG 
GATA3 fw GCGGGCTCTATCACAAAATGA 
GATA3 rv GCTCTCCTGGCTGCAGACAGC 
IL-1β fw GCAATGAGGATGACTTGTTCTTTG 
IL-1β rv CAGAGGTCCAGGTCCTGGAA 
IL-6 fw GGTACATCCTCGACGGCATCT 
IL-6 rv AGTGCCTCTTTGCTGCTTTCAC 
IL-17A fw CCATCCCCAGTTGATTGGAA 
IL-17A rv CTCAGCAGCAGTAGCAGTGACA 
IL-17F fw CAGCGCAACATGACAGTGAA 
IL-17F rv CCAATATCGACAGCAGCAAGTACT 
RORA fw TGAGAGAAGAGCTCCAGCAGATAAC 
RORA rv CACCTCCCGCTGCTTGTTT 
RORA4 fw GCAGCGATGAAAGCTCAAATT 
RORA4 rv CCCTTGCAGCCTTCACATGT 
RORB fw TTTCAACAATGGGCAGTTAGCA 
RORB rv CCAAATGGGACTTAATGATGTTCTG 
RORC1 fw  GACAGGGCCCCACAGAGA 
RORC1 rv TTTGTGAGGTGTGGGTCTTCTTT 
RORC2 fw CAGTCATGAGAACACAAATTGAAGTG 
RORC2 rv CAGGTGATAACCCCGTAGTGGAT 
T-bet fw GATGCGCCAGGAAGTTTCAT 
T-bet rv GCACAATCATCTGGGTCACATT 
 
RESULTS 
   
 - 32 - 
Results 
 
IL-17 is regulated by TGF-β, IL-1β, IL-6 and IL-23 
Understanding the specific functions of T helper cell subsets is important for the 
comprehension of immune regulation and pathological mechanisms. We investigated whether 
in vitro-differentiated Th17 cells differ from other T cell subsets regarding their effector 
function. As the factors required for the differentiation of human Th17 cells are still under 
debate, we first tested several cytokines for their ability to induce Th17-specific genes in 
naïve human T cells. Naïve T cells were stimulated for 7 d with IL-1β, IL-6, IL-21 and IL-23 
or combinations in the presence or absence of TGF-β (Fig. 6A). The highest induction of IL-
17A and IL-17F mRNA is observed in cells cultured with IL-1β, IL-6, IL-23 and TGF-β, with 
or without IL-21. Database search revealed that RORC2 is the closest human homologue of 
mouse RORγt (mRORγt), therefore we included RORC2 in the analysis. High RORC2 
mRNA levels are observed in cells treated with TGF-β, whereas the other cytokines tested 
have a minor effect on RORC2 levels. 
Similar to the IL-17A and IL-17F mRNA data are the results observed for IL-17A protein 
secretion (Fig. 6B). The highest amounts of IL-17A are produced by cells stimulated with 
TGF-β, IL-1β, IL-6, IL-21 and IL-23 (11.9) ng/ml). Interestingly, omission of IL-21 in this 
cytokine cocktail resulted in nearly the same amount of IL-17A (11.5 ng/ml). Taken together, 
these results suggest that TGF-β is sufficient for RORC2 induction, while IL-1β, IL-6 and IL-
23, and to a lesser extend IL-21, are required for production of IL-17A and IL-17F. 
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Fig 6. Regulation of Th17-related genes IL-17A, IL-17F and RORC2. Naïve T cells were stimulated for 7d 
with the cytokines indicated. A) After 6h of restimulation, IL-17A, IL-17F and RORC2 levels were measured by 
real-time PCR and normalized to levels in untreated cells. Mean and standard deviations of triplicates are shown. 
B) After 48h of restimulation, IL-17A secretion was determined by ELISA. n.d. = not detectable. Mean and 
standard errors of duplicates are shown. Data are representative for at least 3 independent experiments. 
 
 
 
Human in vitro-differentiated Th17 cells stimulate IL-6 and IL-1β production in primary 
bronchial epithelial cells  
Next, we wanted to investigate, whether in vitro-differentiated Th17 are a functionally 
distinct T helper cell subset. As IL-17A is known to induce IL-6 in several tissue cells (207), 
we analyzed IL-6 production by normal human bronchial epithelial (NHBE) cells, a primary 
cell line, upon stimulation with Th17 cells. Naïve T cells were cultured for 7 d under 
conditions driving Th1, Th2, Treg and Th17 differentiation (see materials and methods 
section), or without cytokine addition (designated as Th0). After 7 d of differentiation, T cells 
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were washed to remove the differentiation cytokines and were restimulated. To test the 
efficiency of the differentiation process, cytokine profiles of T cells subsets were verified by 
cytometric bead array (data not shown). The function of Treg cells was initially assed by 
suppression assays. T cells were added to NHBE cells and expression of IL-6 was measured 
by real-time PCR (Fig. 7A) and ELISA (Fig. 7B). While NHBE cells cocultured with Th2 and 
Treg cells show only slightly increased IL-6 production compared to cells cultured alone, 
NHBE cells cultured in the presence of Th17 cells produce about 20-times more IL-6 
(3.45±0.5 ng). Th1 and Th0 cells also stimulate IL-6 production in NHBE cells, but to a lesser 
extent. Some IL-6 is detected in Th17 cells, but not in other T cell subsets. Of note, IL-6 
production by NHBE cells also substantially increases when the cells are stimulated with cell-
free supernatants of Th17 cell cultures (Fig. 8A). This observation suggests that cell-cell 
contacts are not necessary for the induction of IL-6. Interestingly, Th17 cells co-cultured with 
NHBE cells produce almost double the amount of IL-17A than Th17 cells cultured alone, 
suggesting a positive feedback loop generated by NHBE cells (Fig. 8B). Even though the T 
cells were washed before co-culturing with epithelial cells, carry-over of the differentiation 
cytokines to the coculture may occur, for example via receptors on the cell surface. To 
exclude that these cytokines account for the observed IL-6 induction, we analyzed, whether 
de novo protein secretion by T cells is required to induce IL-6. Therefore, protein secretion in 
T cells was abolished by preincubating the T cells with Actinomycin D, which inhibits 
transcription, or Brefeldin A, which blocks cytokine secretion (Fig. 8C and D). T cells pre-
treated with these substances are no longer able to induce IL-6 production in epithelial cells, 
showing that production and secretion of cytokines by T cells is needed and the IL-6 
induction is not due to a carry-over of the differentiation cytokines. 
To further confirm that Th17 and Treg cells differ in their modulation of NHBE cells regarding 
IL-6 production, bronchial epithelial cells cultured with Th17 cells and Treg cells were stained 
for IL-6 and analyzed by confocal microscopy (Fig. 7C). In contrast to NHBE-Treg cocultures, 
there is a clear IL-6 cytokine staining in most of the NHBE cells cultured in the presence of 
Th17 cells, consistent with our results obtained by real-time PCR and ELISA. 
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Fig 7. Th17 cells stimulate IL-6 production by bronchial epithelial cells. NHBE cells were cultured alone or 
in presence of T cells. A) After 6 h, IL-6 mRNA was quantified by real-time PCR and normalized to levels in 
NHBE cells cultured alone. Mean and standard deviations of triplicates are shown. B) IL-6 was measured by 
ELISA after 48 h of coculture. Mean and standard errors of duplicates are shown. C) NHBE cells were cultured 
in presence of Treg or Th17 cells. After 30 h, NHBE cells were stained with DAPI and anti-IL-6 antibodies and 
analyzed by confocal microscopy. Data shown are representative for 3 independent experiments.  
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Fig 8. Regulation of IL-6 and IL-17A expression in T cells and NHBE cells. A) NHBE cells were cultured 
for 48 h with supernatants from different T cell subsets. IL-6 protein secretion was measured by ELISA. B) 
NHBE cells were cultured with T cells differentiated to different subsets. After 48 h of coculture, IL-17A protein 
secretion was measured by ELISA. C) T cells differentiated to Th0 and Th17 cells were treated for 1 h with 
Brefeldin A (BFA) or Actinomycin D (ActD), or left untreated. After washing, the T cells were cocultured with 
NHBE cell for 6 h to analyze IL-6 expression by real-time PCR (C) or for 48 h to measure IL-6 protein by 
ELISA (D). E) NHBE cells were cultured for 48 h with recombinant IL-17A (rhIL-17A) or with Th17 cells in 
the presence or absence of neutralizing anti-IL-17A antibodies. IL-6 protein secretion was measured by ELISA. 
Mean and standard errors of duplicates are shown. Data are representative for at least 3 independent 
experiments. 
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Beside IL-6, we find IL-1β to be highly increased in NHBE-Th17 cocultures compared to 
NHBE cells cultured alone or together with Treg cells (Fig. 9A and 9B, upper left panel). 
Furthermore, increased levels of IL-8, G-CSF and GM-CSF are observed in NHBE cells 
cocultured with Th17 cells (Fig. 9B). 
 
                         
 
Fig 9. Th17 cells stimulate cytokine and chemokine production by bronchial epithelial cells. NHBE cells 
were cocultured with T cells. A) After 6 h, IL-1β mRNA levels were measured by real-time PCR and normalized 
to levels in NHBE cells cultured alone. Mean and standard deviations of triplicates are shown. B). After 48 h, 
IL-1β, IL-8, G-CSF and GM-CSF concentrations were determined by cytometric bead array. Mean and standard 
errors of duplicates are shown. Data are representative for 3 independent experiments.  
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Taken together, these findings show that human in vitro-differentiated Th17 cells make up a 
distinct effector subset, which substantially differs from other T helper cells subsets in its 
ability to induce production of pro-inflammatory cytokines by primary bronchial epithelial 
cells. 
 
RORC2 is highly expressed in Th17 cells and in cells differentiated under Treg conditions 
The human ROR-subfamily consists of three members: RORA, RORB and RORC (Fig. 10A). 
Human RORC (hRORC) as well as mouse RORγ (mRORγ) exist in two isoforms. mRORγ 
and its isoform mRORγt are identical from exon 3 to 11, while exon 2 is missing in mRORγt. 
Each of the isoforms contains a distinct exon 1. The same pattern is observed for hRORC1 
and hRORC2. hRORC2 shows the same exon configuration as mRORγt, while hRORC1 
corresponds to mRORγ.  
The sequence homology of mRORγt and hRORC2 as well as two recent publications suggest 
RORC2 to be the key transcription factor for differentiation towards human Th17 cells (162, 
163). To investigate whether RORC2 is selectively expressed in the Th17 subset of T helper 
cells, naïve T cells were differentiated under Th1, Th2, Treg or Th17 conditions and expression 
of their lineage-specific transcription factors was measured (Fig. 10B). Interestingly, high 
levels of RORC2 mRNA are found not only in Th17, but also in Treg cells, while Th1 and Th2 
cells show only low RORC2 expression. T-bet, GATA3 and FOXP3, on the other hand, are 
specifically expressed in Th1, Th2 and Treg cells, respectively, showing that differentiation 
generated distinct T helper cell populations.  
Recently, RORα, specifically isoform 4, has been suggested to play an important role in 
murine Th17 development (167). To test whether RORA, the human homologue of mouse 
RORα, is specifically expressed in Th17 cells, Th1, Th2, Treg and Th17 cells were analyzed 
for the expression of RORA (all isoforms), RORA4 (isoform 4) and RORC2 (Fig. 10C). 
While expression of RORA and RORA4 is slightly higher in Th17 and Treg cells, the 
differences to levels in Th1 and Th2 are not as clear as for RORC2. Next, we analyzed the 
expression of RORC2 in different leukocytes. Monocytes (CD14+), B cells (CD19+), natural 
killer (NK) T cells (CD3+CD56+), CD4+CD25- cells, CD4+CD25+ cells and cytotoxic T cells 
(CD8+) were stimulated with and without TGF-β and are analyzed for RORC2 and IL-17A 
mRNA expression (Fig. 10D). While RORC2 expression is low in CD14+ and CD19+ cells, 
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high levels of RORC2 are found in CD3+CD56+ and CD8+ cells. Both CD4+CD25- and 
CD4+CD25+ cells highly express RORC2, whereas IL-17A, in contrast, is high only in 
CD4+CD25- cells, but cannot be detected in CD4+CD25+ cells, consistent with the suppressive 
role of these cells. Given the high expression of RORC2 in NKT cells, isolated using the 
surface markers CD3 and CD56, we wanted to exclude the possibility that contaminating 
activated T cells, which also express CD3 and CD56, are the source of RORC2. Therefore, 
we depleted activated T cells from NKT cells according to the activation markers CD25 and 
CD69 (Fig. 11A). PMBC were stained with antibodies against CD3, CD56, CD25 and CD69 
and the CD3+CD56+CD25-CD69- population was isolated by FACS sorting. Real-time PCR 
analysis of these cells revealed a RORC2 expression similar to the expression detected in 
CD3+CD56+ cells, indicating that activated T cells are not the main source of the high RORC2 
levels observed (Fig. 11B). 
In conclusion, our findings show that neither RORC2 nor RORA are likely to be specific 
markers for human Th17 cells, as both are also highly expressed under Treg conditions and do 
not necessarily implicate IL-17 expression. 
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Fig 10. Expression of ROR-family members in T cell and leukocyte subsets. A) Schematic depiction of 
mouse and human ROR-family members. hRORC2 shares its exon configuration with mRORγt, while hRORC1 
corresponds to mRORγ. hRORA is the homologue of mRORα. B) T cell subsets were analyzed for the 
expression of T-bet, GATA3, FOXP3  and RORC2. Lowest expression level of each transcription factor was set 
to 1. C) T cell subsets were analyzed for RORA, RORA4 and RORC2 expression. Primers recognizing all 
isoforms of RORA (RORA) and primers recognizing specifically isoform 4 (RORA4) were used for real-time 
PCR. Lowest expression level of each transcription factor was set to 1. D) Different leukocyte subsets were 
stimulated for 12 h with or without TGF-β. RORC2 (left scale) and IL-17A (right scale) mRNA levels were 
determined by real-time PCR. Error bars represent standard deviations of triplicates. Data are representative for 
at least 3 independent experiments.  
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Fig 11. RORC2 expression in CD3+CD56+CD25-CD69- cells. A) PMBC were stained with antibodies against 
CD3, CD56, CD25 and CD69 and the CD3+CD56+CD25-CD69- population was isolated by FACS. B) After 
stimulation for 12 h with or without TGF-β, RORC2 (left scale) and IL-17A (right scale) mRNA levels were 
determined by real-time PCR. Error bars represent standard deviations of triplicates. Data are representative for 
3 independent experiments.  
 
 
TGF-β is necessary and sufficient to induce RORC2 in human T cells 
As RORC2 is highly expressed in conditions with TGF-β (Fig. 6A), we asked the question, 
whether TGF-β regulates its expression. Naïve T cells were stimulated with anti-CD3 and 
anti-CD28 antibodies and a dose-titration of TGF-β was performed (Fig. 12A and 12B). 
While RORC2 is dose-dependently induced by TGF-β (Fig. 12A), IL-17A and IL-17F show a 
maximal expression at a concentration of 5 ng/ml (Fig. 12B). This concentration was 
previously found to be optimal for IL-17A and IL-17F expression when combined with other 
Th17-differentiating cytokines (data not shown). To further confirm these data and to see, 
whether TGF-β is required for RORC2 expression, we cultured naïve T cells for 7 d under 
Th17 conditions in the presence of neutralizing anti-TGF-β antibodies and measured RORC2 
expression by real-time PCR (Fig 12C). Consistent with its dose-dependent induction by 
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TGF-β, RORC2 expression decreases with increasing concentrations of neutralizing 
antibodies. Taken together, these results suggest a strong dependency of RORC2 on TGF-β. 
 
 
 
   
 
 
 
Fig 12. Effect of TGF-β  on IL-17A, IL-17F and ROR-family members. Naïve T cells were stimulated with 
anti-CD3 and anti-CD28 antibodies and a TGF-β dose-titration was performed. At d 7, mRNA levels of RORC2 
(A), IL-17A (B) and IL-17F (B) were measured by real-time PCR. C) Naïve T cells were stimulated under Th17 
conditions together with neutralizing anti-TGF-β antibodies. At d 7, RORC2 levels were measured. D) Naïve T 
cells were stimulated with or without TGF-β and expression of RORA, RORA4, RORB, RORC1 and RORC2 
was measured by real-time PCR. n.d.: not detectable. Error bars represent standard deviations of triplicates. Data 
are representative for at least 3 independent experiments. 
 
         
 
A short-term kinetic (Fig 13A) and a long-term kinetic (Fig 13B) of RORC2 were performed. 
While RORC2 levels continuously decrease in the absence of TGF-β, there is a first peak of 
RORC2 expression between 9 h and 12 h if TGF-β is added in the beginning of the culture. A 
second, higher peak is observed at day three, which might reflect the expansion of a Th17 
and/or Treg population. At this time-point, the difference between cells stimulated with and 
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without TGF-β is maximal. The highest RORC2 expression is observed when cells, initially 
treated with TGF-β, are restimulated at day 7.  
 
 
 
 
 
Fig 13. Time-kinetic of RORC2 expression. CD4+ T cells were stimulated with anti-CD3 and anti-CD28 
antibodies and treated with (black) or without (white) TGF-β. RORC2 mRNA expression was determined by 
real-time PCR after 0 h, 6 h, 9 h, 12 h and 24 h (A), and after 0 h, 12 h, 3 d and 7 d, with and without 
restimulation at d 7. Levels in ex vivo samples (0 h) were set to 1. (B). Mean and standard deviations of 
triplicates are shown. Data are representative for at least 3 independent experiments. 
 
 
To test whether the dependency on TGF-β applies also for the other ROR-family members, 
cells were stimulated for 7 d with or without TGF-β and mRNA levels of RORA (all 
isoforms), RORA4 (isoform 4), RORB, RORC1 and RORC2 were determined (Fig 12D). Of 
all genes tested, only RORC2 increases upon stimulation by TGF-β, fitting to its role in Th17 
cell differentiation, which is dependent on TGF-β. 
Next, we wanted to investigate if other Th17-differentiating cytokines affect RORC2 gene 
regulation. Therefore, naïve T cells were cultured for 7 d with IL-6, IL-1β or IL-23 in the 
presence or absence of TGF-β (Fig. 14A). None of these cytokines, except TGF-β, 
upregulates RORC2. Furthermore, combining the cytokines with TGF-β does not lead to a 
significant higher RORC2 expression compared to induction by TGF-β alone. This shows that 
of all cytokines important for Th17 differentiation, only TGF-β upregulates RORC2. Also 
other cytokines like IL-2, IL-4, IFN-γ, IL-10, IL-21, IL-27, TNF-α, or the lipidic mediator 
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retinoic acid (RA), do not upregulate RORC2 mRNA (Fig. 14B). Instead, IL-4 and RA, and 
to a lesser extent also IFN-γ, IL-10 and IL-27, reduce the TGF-β-mediated RORC2 induction.  
In summary, our results show that in vitro-differentiated Th17 cells make up a distinct 
effector subset as they differ in their potency to induce IL-6 and IL-1β in NHBE cells. TGF-β 
is necessary and sufficient for the induction of RORC2, which is expressed under Th17 but 
also under Treg conditions. In contrast, IL-1β, IL-6 and IL-23 are required for the expression 
of IL-17A and IL-17F and for Th17-specific effector functions. 
 
 
                   
 
Fig 14. TGF-β  is essential and sufficient for RORC2 induction. A) Naïve T cells were stimulated as 
indicated. At d 7, levels of RORC2 were measured. Statistical significance was tested using unpaired t tests (** 
P ≤ 0.01, *** P ≤ 0.001). B) Naïve T cells were stimulated for 7 d as indicated and RORC2 levels were 
determined. RA: Retinoic acid. Mean and standard deviations of triplicates are shown. Data are representative 
for at least 3 independent experiments. 
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Fig 15. Effect of TGF-β  on IL-17A and RORC2 in naïve and memory cells. Memory (CD45RA-) and naïve 
(CD45RA+) T cells were cultured under Th17 conditions in the presence or absence of TGF-β, or with 
neutralizing anti-TGF-β antibodies. A) Expression of IL-17A and RORC2 was measured by real-time PCR. 
Levels were normalized to levels in untreated cells of the corresponding population. Mean and standard 
deviations of triplicates are shown.  B) IL-17A protein expression was measured by ELISA. Mean and standard 
errors of duplicates are shown. Data are representative of at least 3 independent experiments. 
RESULTS 
   
 - 46 - 
Discussion 
 
This study demonstrates that human Th17 cells represent a functionally distinct subset of T 
helper cells that clearly differs from Treg cells in its ability to modulate gene expression in 
primary bronchial epithelial cells, although both subsets share RORC2 expression. 
Epithelial cells have been reported to produce IL-6 upon stimulation with recombinant IL-
17A (207), and elevated levels of both IL-6 and IL-17A have been found in plasma and 
airways of asthmatic individuals (213, 217). Our data showing that in vitro-differentiated 
Th17 cells, in contrast to Treg cells, potently induce IL-6 production by primary bronchial 
epithelial cells provide a further link between these cytokines and are a hint that Th17 cells 
contribute to airway inflammation in acute asthma. In addition, Th17 cells up-regulate G-
CSF, GM-CSF and IL-8 production by bronchial epithelial cells, consistent with their role in 
granulopoiesis and attraction of neutrophils (143, 218). Th17 cells as well as supernatants 
from Th17 cell cultures induce higher levels of IL-6 than equal amounts of recombinant IL-
17A, and this induction cannot be fully abrogated by anti-IL-17A antibodies (Fig. 8E). 
Therefore, we speculate that other Th17 cytokines such as IL-22, IL-26 or IL-17F, which 
have been described to regulate inflammatory responses (219), synergize with IL-17A in the 
induction of proinflammatory cytokines in epithelial cells. The fact that Th17 cells cocultured 
with bronchial epithelial cells produce more IL-17A than T cells cultured alone indicates that 
Th17 cells propagate the differentiation of their own population through induction of pro-
inflammatory cytokines like IL-6 and IL-1β; a positive feedback mechanism observed for 
other Th subsets. 
Th17 cells express the transcription factor RORC2, which has very recently been shown to 
play a crucial role in Th17 differentiation (162, 163). We observe high levels of RORC2 also 
in CD8+ as well as in NKT cells, consistent with the expression of IL-17A in these cells (220-
222). However, RORC2 is also expressed in cells differentiated towards Treg cells, as well as 
in naturally occurring CD25+ Treg cells, which do not express IL-17A. This result suggests that 
the presence of RORC2 does not necessarily implicate IL-17A production. Expression of IL-
17A in Treg cells might be suppressed by FOXP3, which we detect selectively in Treg, but not 
in Th17 cells. A hint for such a repression comes from two recent studies showing that Foxp3 
antagonizes RORγt in mice (14, 15). These findings suggest that RORC2, although important 
for Th17 development, is not a selective marker for IL-17-producing cells and that 
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investigation of Th17 cells requires an assessment of additional characteristic genes such as 
IL-17A or IL-17F. 
The factors required for the development of human Th17 cells are controversially discussed in 
literature. We found that TGF-β, the proinflammatory cytokines IL-1β and IL-6, as well as 
IL-23 are required for an efficient production of IL-17A and IL-17F and for the development 
of a functional Th17 effector population. A recent publication suggests a role for IL-21 in the 
development of human Th17 cells (164). Consistently, we observe a slight IL-17A induction 
by TGF-β and IL-21. However, the addition of IL-21 to the cytokine cocktail TGF-β, IL-1β, 
IL-6 and IL-23 does not lead to a further enhancement of IL-17A and IL17F. As Th17 cells 
have been described as a source of IL-21 (92), it might be that the cells cultured with TGF-β, 
IL-1β, IL-6 and/or IL-23 secrete substantial levels of IL-21, which then acts in an autocrine 
manner, overcoming an effect of supplemental IL-21.  
The necessity for TGF-β in the development of human Th17 cells is currently under debate. 
In serum-free conditions we observe a crucial role for TGF-β in the induction of Th17-
specific genes IL-17A, IL-17F and RORC2. The discrepancy in the question whether TGF-β 
is required or not might be due to differences in culture conditions such as usage of serum. It 
is anticipated that an appropriate concentration of TGF-β is crucial and that highly dosed 
TGF-β suppresses IL-17, as observed for many cytokines. Furthermore, TGF-β might be 
required at the beginning of the Th17 development, but at later stages rather inhibit IL-17 
production. This is supported by our observation that neutralizing anti-TGF-β antibodies 
decrease IL-17 production in naïve T cells cultured under Th17 conditions, whereas these 
antibodies do not affect IL-17 production in memory cells (Fig. 15). Consistent with these 
results, a recent publication suggests that TGF-β is not required for IL-17 induction in 
memory cells (223). 
Our data suggest that TGF-β contributes to the development of Th17 cells through induction 
of their transcription factor RORC2. None of the other cytokines important for Th17 cell 
development upregulates RORC2, nor do they synergize with TGF-β. Furthermore, TGF-β-
induced RORC2 expression is inhibited by IL-4 and RA, which were reported to antagonize 
Th17 lineage commitment (2, 3, 60). The mechanisms underlying this inhibition, however, 
are still unclear. In conclusion, this study identifies a crucial role for TGF-β in the induction 
of the transcription factor RORC2. The fact that RORC2 expression does not always 
implicate IL-17 expression highlights the need for additional markers to identify Th17 cells in 
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disease. By comparing effector functions of different T helper cell subsets, we identify a 
strong capacity of human Th17 cells in the induction of highly proinflammatory cytokines in 
primary bronchial epithelial cells, suggesting a role for Th17 cells not only in autoimmune 
disorders, but also inflammatory airway diseases. 
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2.2 RORC2 is involved in T cell polarization through interaction with the 
FOXP3 promoter 
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Abstract 
 
The process of T helper cell differentiation towards effector T cells is important to tailor 
specific immunity to invading pathogens, while tolerating harmless or autologous antigens. 
Identification of the mechanisms underlying this polarization process is therefore central to 
understand how the immune system confers immunity and tolerance. The present study 
demonstrates that RORC2, a key transcription factor in Th17 cell development, inhibits 
FOXP3 expression in human T cells. While over-expression of RORC2 in naïve T cells 
reduces levels of FOXP3, siRNA-mediated knockdown of RORC2 enhances its expression. 
RORC2 mediates this inhibition at least partially by binding to two out of four ROR-
responsive elements (ROREs) on the FOXP3 promoter. Knockdown of RORC2 promotes 
high FOXP3 levels and decreased expression of pro-inflammatory cytokines IL-1β, IL-6, IL-
17A IFN-γ and TNF-α in differentiating naïve T cells, suggesting that the role of RORC2 in 
Th17 cell development involves not only induction of Th17-characteristic genes, but also 
suppression of Treg-specific programs. Together, this study identifies RORC2 as a polarizing 
element in transcriptional cross-regulation and provides novel viewpoints on the control of 
immune tolerance versus effector immune responses. 
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Introduction 
 
CD4+ effector cells can be divided into different subsets according to their phenotype and 
function. Each subset is crucial for mounting an appropriate immune response to a certain 
type of pathogen (205, 224). Differentiation of naïve T helper cells towards a specific effector 
subset is therefore an important process in immune system homeostasis. T cell development is 
governed by lineage-specific transcription factors that regulate expression of characteristic 
surface receptors and cytokines. The Th1-specific transcription factor T-bet, for example, 
coordinates production of IFN-γ and TNF-α (16), while the GATA-binding protein 3 (GATA-
3) regulates Th2 development including production of their characteristic cytokines IL-4, IL-
5, IL-9 and IL-13 (20). Development of Th17 cells and expression of their specific cytokines 
IL-17A, IL-17F and IL-26 is orchestrated by the retinoic acid receptor-related orphan receptor 
γt/C2 (RORγt/RORC2) (153). While these effector subsets - Th1, Th2 and Th17 - are 
specialized to mount an immune response in order to tackle invading pathogens, regulatory T 
(Treg) cells in contrast control the strength and duration of the response and establish 
tolerance to harmless self- and non-self antigens. Failure in either development or function of 
Treg cells is a major cause of autoimmune and inflammatory disorders. Forkhead box protein 
3 (FOXP3) is the master regulator of Treg cells. Retroviral gene transfer of FOXP3 is 
sufficient to convert naïve T cells into a regulatory T cell phenotype (67) and confers 
suppressor function on peripheral CD4+CD25- T cells (68, 69). Expression of FOXP3 is 
regulated through interaction of several TCR-induced transcription factors, including NFAT, 
AP-1, cAMP response element-binding protein (CREB)/activating transcription factor (ATF), 
with the promoter or an enhancer element of the foxp3 gene (74, 75, 80, 225, 226). However, 
isolated TCR-stimulation appears not to be sufficient for high levels of FOXP3 expression 
and IL-2, TGF-β and IL-27 have been reported to act as enhancing factors in FOXP3 gene 
regulation (76-78, 80, 82).  
Cross-inhibition of T cell subsets during differentiation is an important mechanism to ensure 
expansion of the desired population. This is partially mediated through cytokines produced by 
one subset that inhibit development of other subsets. However, the lineage-specific 
transcription factors also play an important role in cross-regulation of T cell subpopulations. 
T-bet inhibits development of Th2 by binding to their master regulator GATA-3, preventing it 
from DNA binding and activation of Th2-specific genes (10, 11). Likewise, GATA-3 can 
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down-regulate STAT4, a transcription factor important for Th1 development (12). By binding 
to GATA-binding sites in the FOXP3 promoter, GATA-3 also negatively regulates FOXP3 
expression and thereby inhibits Treg development (13). The Th17-driving transcription factor 
RORC2 is expressed by both Treg and Th17 cells, while only Treg cells express FOXP3 (14, 
227, 228). In Treg cells, FOXP3 suppresses transcriptional activity of RORC2 by direct 
interaction, thereby inhibiting Th17 development (14, 15).  
RORC2 belongs to the family of retinoic acid receptor (RAR)-related orphan receptors 
(RORs). This subfamily consists of three members: RORA (NR1F1, RORα, RZRα), RORB 
(NF1F2, RORβ, RZRβ) and RORC (NF1F3, RORγ, RZRγ). ROR genes generate several 
isoforms that differ only in their N-termini (168-170). Proteins of the ROR family display a 
typical nuclear receptor domain structure consisting of four domains: an N-terminal domain, a 
highly conserved DNA-binding domain (DBD), a hinge domain and a C-terminal ligand-
binding domain (LBD). The DBD binds to DNA containing a so-called ROR-response 
element (RORE), which consists of the DNA sequence GGTCA as a core motive, preceded 
by an A/T-rich sequence (171, 172). In contrast to other nuclear receptors, ROR family 
proteins bind DNA as monomers (169, 171, 173). They can interact with both coactivators 
and corepressors to positively or negatively regulate transcription of target genes and are 
involved in a wide range of developmental processes. RORC plays a key role in the 
development of lymph nodes and Peyer’s patches and in the regulation of thymopoiesis (170, 
198-200).  
In contrast to T-bet, GATA-3 and FOXP3, RORC2 has not been described to participate in 
cross-regulation of T cell subsets. Based on our observation that GATA3 inhibits FOXP3 
expression (13), we hypothesized that the preference for Th17 over Treg cells might be 
mediated through restriction of the foxp3 gene by RORC2. The present study describes a role 
for RORC2 in T cell cross-regulation by negatively regulating FOXP3 expression, which 
involves binding of RORC2 to the FOXP3 promoter region. 
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Materials and Methods 
 
Isolation of naïve T cells 
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coats of healthy donors 
using Ficoll (Biochrom KG) density gradient centrifugation. CD4+ T cells were purified using 
anti-CD4 magnetic beads and Detach-a-Bead antibodies (Dynal). CD45RA+ cells were 
isolated using MACS magnetic beads (Miltenyi Biotec GmbH).  
 
Differentiation of Treg and Th17 cells 
CD45RA+ T cells were stimulated with soluble anti-CD3 and anti-CD28 antibodies (4 µg/ml) 
in serum-free AIM-V medium (Life Technologies) supplemented with IL-2 (25 U/ml, Proreo 
Pharma AG). Anti-CD3 and anti-CD28 antibodies were produced using the hybridoma cell 
line OKT3 (American Type Tissue Collection) and the hybridoma cell line 15E8 (CLB). Treg 
cells were generated in the presence of TGF-β (5 ng/ml, R&D) and neutralizing anti-IL-12 (5 
µg/ml, R&D) and anti-IFN-γ (1 µg/ml, R&D) antibodies. Th17 cells were differentiated as 
previously described (228) in the presence of TGF-β, IL-6 (20 ng/ml, PeproTech EC), IL-1β 
(10 ng/ml, PeproTech EC), IL-23 (10 ng/ml, eBioscience) and neutralizing anti-IL-12 and 
anti-IFN-γ antibodies. Dose titrations were performed and the optimal dose for each cytokine 
and antibody was determined in preliminary experiments.  
 
Isolation of RNA, cDNA synthesis and quantitative RT-PCR 
Total RNA was isolated using the RNeasy mini kit (Qiagen) according to the manufacturer's 
protocol. Reverse transcription was performed with TaqMan reverse transcription reagents 
(Fermentas) using random hexamer primers according to the manufacturer's protocol. 
PCR primers were designed based on the sequences reported in GenBank using the Primer 
Express software version 1.2 (Applied Biosystems). Primers used for relative quantification 
are listed in table 1. All primers are spanning intron-exon borders and have been verified for 
efficacy over a 4-log concentration range. The prepared cDNAs were amplified using iTaq 
SYBR Green Supermix with ROX (BioRad) according to the manufacturer’s 
recommendations in an ABI PRISM 7900 Sequence Detection System (Applied Biosystems). 
Relative quantification and calculation of the range of confidence was performed using the 
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comparative ΔΔCT method. EF-1α was used as endogenous control. All amplifications were 
conducted in triplicates. 
 
Determination of cytokine concentration 
T cells were cultured for 5 d under Th17 conditions. Before restimulation with soluble anti-
CD3 and anti-CD28 antibodies (4 µg/ml), the cells were washed to remove the cytokines used 
for differentiation. Supernatants were collected 48 h after restimulation and concentrations of 
IL-1β, IL-2, IL-5, IL-6, IL-13, IL-17A, IFN-γ and TNF-α were determined by cytometric 
bead array (BioRad) according to the manufacturer's protocol. 
 
Western blotting 
Protein extraction was performed as follows: The cells were pelleted and resuspended in 
buffer C (20 mM HEPES (pH 7.9), 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM 
DTT, protease inhibitors (Roche Diagnostics), and 0.1% Nonidet P-40), and incubated at 4 °C 
with agitation for 15 min. Insoluble material was removed by centrifugation and the 
supernatants were diluted 1/3 with buffer D (as buffer C, but without NaCl). Total protein 
concentrations were determined by a colorimetric protein assay (BioRad). Samples were 
loaded next to a prestained protein-mass ladder (Invitrogen Life Technologies) on a NuPAGE 
4–12% bis-Tris gel (Invitrogen Life Technologies). The proteins were electroblotted onto a 
polyvinylidene difluoride membrane (Amersham Biosciences). Unspecific binding was 
blocked with TBS-Tween 5% BSA. After blocking, the membrane was incubated with an 
anti-RORγ antibody (Santa Cruz Biotechnology) in a 1:500 dilution in blocking buffer over 
night at 4 °C. Next, the membrane was washed and incubated with an anti-rabbit HRP labeled 
Ab (Cell Signaling, 1:3000) at RT for 1 h. The blot was developed using an ECL plus 
Western Blot Detection System (GE Healthcare) and visualized with a LAS 1000 camera 
(Fuji). To confirm equal sample loading and transfer, membranes were stripped, re-blocked 
and re-probed using an anti-GAPDH antibody (6C5, Ambion Ltd.).  
 
Flow cytometry 
Cells were stained with the CD25 mAb (Beckman Coulter) prior to FOXP3 intracellular 
staining, which was performed according to the manufacturer's protocol using 
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AlexaFluor®488 anti-human FOXP3 Flow kit (295D; Biolegend). Matched isotype controls 
were used at the same protein concentration as the respective antibodies.  
Cell acquisition by flow cytometry was done on a Four-color FACS EPICSTM XL-MCL 
(Beckman Coulter) using the software ExpoTM32 version for data acquisition and evaluation.  
 
Amplification of FOXP3 promoter fragments 
FOXP3 promoter fragments were amplified by conventional PCR using a biotinylated reverse 
primer (5’-bio-ACCTTACCTGGCTGGAATCACG-3’) situated 177 bp downstream of the 
TSS. Multiple forward primers were designed to generate FOXP3 promoter fragments of 
decreasing length (table 2). The position of the primers are depicted in Fig. 19A. Reactions 
were conducted in 75 mM Tris HCl pH 8.8, 20 mM (NH4)2SO4, 2 mM MgCl2, 0.2 mM dNTP, 
0.2 µM of each primer, 6 µg/ml template DNA (pGL4 FOXP3 -1210 /+177) and 1.25 U of 
Taq DNA polymerase (Fermentas). The same PCR conditions were used for the amplification 
of all the products: Initial denaturation step (2 min, 94 °C), 42 cycles of 94 °C for 30 s, 56 °C 
for 30 s, 72 °C for 60 s, final elongation step (7 min, 72 °C). PCR products were purified by 
ethanol precipitation. For this purpose 1/10 volume of 3 M sodium acetate and 3 volumes of 
100% ethanol were added to the PCR products and samples were mixed, precipitated for 1 h 
at -80 °C and harvested by centrifugation (30 min, maximum speed, 4 °C). The supernatant 
was removed, residual ethanol was allowed to evaporate and the pellet was eluted in blocking 
buffer (PBS, 0.1% BSA, 0.05% Tween20). To quantify the FOXP3 promoter fragments, 
samples were loaded next to a MassRuler DNA Ladder Mix (Fermentas) on a 1% agarose gel 
and quantified using the AIDA image analyzer software (Raytest). For fragment F11 and for 
competitor oligonucleotides, sense and antisense oligonucleotides (Microsynth, sequences in 
table 2) were annealed for 10 min at 95 °C. 
 
FOXP3 promoter ELISA 
Protein extraction was performed as described for Western blotting. 384-well flat bottom 
plates were precoated with streptavidin (Pierce) and were washed 3 times with washing buffer 
(PBS, 0.05% Tween20). Biotinylated FOXP3 promoter fragments or consensus sequences 
were added (1 pmol per well; 50 fmol/µl) and incubated for 1 h at RT. Upon 3 wash cycles, 
nuclear extracts were added at concentration of 1 µg/µl and incubated overnight at 4 °C in the 
presence of 10 µg of poly(deoxyinosinic-deoxycytidylic) acid (Sigma-Aldrich) to block 
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unspecific binding. The plate was washed 3 times with buffer C/D and then incubated with 
the primary antibody (rabbit antiRORC, 1:200 in buffer C/D, Biolegend) at 4 °C for 2 h.  
After 3 wash cycles with buffer C/D, a secondary antibody (anti rabbit IgG-HRP, 1:3000 in 
buffer C/D, Cell Signaling) was added and the plate was incubated for 1 h at 4 °C. The wells 
were washed 4 times with buffer C/D before substrate reagent was added (R&D system). The 
colorimetric reaction was stopped after 2 to 5 min by adding 2 M H2SO4. Absorbance at 
450 nm was measured using a Mithras microplate reader (Berthold Technologies). 
 
Transfections  
Naïve T cells were pre-activated overnight in serum-free AIM-V medium (Life Technologies) 
containing soluble anti-CD3 and anti-CD28 antibodies (4 µg/ml). 6-10 x 106 T cells were 
transfected with 3 µg of pcDNA3.1-empty, pcDNA3.1-RORC2FL or pcDNA3.1-
RORC2ΔDBD plasmids in 100 µl of NucleofectorTM solution (Amaxa Biosystems) using the 
T-23 program. SiRNA oligos (Ambion) were transfected at a concentration of 30 nM. 
Optimal concentrations were determined in preliminary experiments (Fig. 16). Two different 
siRNA oligos were tested and oligo siRNA1 was used in subsequent experiments. SiRNA 
sequences are listed in table 3. 8 h after transfection with plasmids or siRNA, the medium was 
replaced with fresh, serum-free AIM-V medium and cells were stimulated with anti-CD3 and 
anti-CD28 antibodies (4 µg/ml) or as indicated.  
HEK cells were plated in 6 well dishes and transfected with of pcDNA3.1-empty, pcDNA3.1-
RORC2FL or pcDNA3.1-RORC2ΔDBD plasmids at 90-95% confluence using the 
lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s instruction. 
 
Reporter gene assays 
6-10 x106 naïve T cells were co-transfected with of 3 µg of the pGL4-empty or the pGL4-
FOXP3 promoter luciferase reporter vector and 2 µg of pcDNA3.1-empty, pcDNA3.1-
RORC2FL or pcDNA3.1-RORC2ΔDBD plasmids in 100 µl of NucleofectorTM solution. 
Electroporation was performed using the T-23 program. After 8 h, the medium was replaced 
with fresh serum-free AIM-V medium and cells were stimulated with anti-CD3 and anti-
CD28 antibodies (4 µg/mL) for another 12 h until luciferase activity in cell lysates was 
measured using the dual luciferase assay system (Promega Biotech) in a Berthold Lumat LB 
9507 luminometer according to the manufacturer’s instructions.  
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Plasmids 
The human FOXP3 promoter was cloned into the pGL4 vector (Promega Biotech) to generate 
the pGL4 FOXP3 -1210/+177 as previously described (74). Human RORC2FL and 
RORC2ΔDBD were cloned into a pcDNA3.1 vector (Invitrogen) using the primers listed in 
table 4. 
 
Bioinformatics 
Alignments of the human FOXP3 promoter were performed using the Genomatix software 
(http://www.genomatix.de). 
 
 
 
Table 1. Primers used for RT-PCR 
EF-1α fw CTGAACCATCCAGGCCAAAT 
EF-1α rv GCCGTGTGGCAATCCAAT  
FOXP3 fw GAAACAGCACATTCCCAGAGTTC 
FOXP3 rv ATGGCCCAGCGGATGAG 
RORC2 fw CAGTCATGAGAACACAAATTGAAGTG 
RORC2 rv CAGGTGATAACCCCGTAGTGGAT 
 
Table 2. Primers and oligonucleotides used for promoter ELISA 
P-1116fw GACATGTTCAGCACTGTATCTGACCC 
P-1006fw AGTAAAAGACCCCAAAGGCTGAGG 
P-896fw CATTAATATTGGGGACCTGCTAGGG  
P-511fw TTCCCATCCACACATAGAGC 
P+1fw AAGCCAGGCTGATCCTTTTCTGT 
P+176rv-bio bio-ACCTTACCTGGCTGGAATCACG 
F11 sense TCTGGTACAGTGGGATGTACCCAGCTACCGTGATTCCA
GCCAGGTAAGGT 
F11 antisense ACCTTACCTGGCTGGAATCACGGTAGCTGGGTACATCC
CACTGTACCAGA 
Competitor WT sense TACGCAGCTGAAATGAGGTCAGGCAGACTA 
Competitor WT antisense TAGTCTGCCTGACCTCATTTCAGCTGCGTA 
Competitor MUT antisense TACGCAGCTGAAATGCCTAGCGGCAGACTA 
Competitor MUT antisense TAGTCTGCCGCTAGGCATTTCAGCTGCGTA 
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Table 3. SiRNA oligos 
SiRNA1 sense CAAUCUCUCUUAUCCUUGAtt 
SiRNA1 antisense UCAAGGAUAAGAGAGAUUGtg 
SiRNA2 sense CCCUGACAGAGAUAGAGCAtt 
SiRNA2 antisense UGCUCUAUCUCUGUCAGGGag 
 
Table 4. Primers used for cloning 
RORC2FLfw GAGAGGTACCGACATGAGAACACAAATTGAAGTGATCCC 
RORC2ΔDBDfw GAGAGGTACCGACATGCTGTCAAGTTCGGCCGCAT 
RORC2rv ATATGCGGCCGCTCACTTGGACAGCCCCACAGGT 
 
 
 
 
 
Fig 16. Dose-titration and time-kinetic of siRNA oligonucleotides against RORC2. A, Naïve CD4+ T cells 
were transfected with two different siRNA oligonucleotides against RORC2 at increasing concentrations. After 
48 h RORC2 mRNA expression was determined by RT-PCR. Levels in scrambled siRNA transfected cells was 
set to 100%. Bars represent mean and standard deviation of 3 independent experiments. B, Naïve CD4+ T cells 
were transfected with siRNA1 at a concentration of 30 nM. RORC2 mRNA levels were determined by RT-PCR 
after different time points. Expression at time-point 0 h was set to 100% and levels at each time points were 
normalized to levels in scrambled siRNA transfected cells at the same time point. Bars represent mean and 
standard deviation of 3 independent experiments. (siScram = scrambled siRNA) 
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Results 
 
Over-expression of RORC2 reduces FOXP3 expression 
While RORC2 activity is inhibited by FOXP3 in Treg cells, this inhibitory function appears to 
be abolished in Th17 cells. Considering the key roles of lineage-specific transcription factors 
in mutual inhibition of T cell subsets, RORC2 itself represents a candidate for this 
unidentified suppressor of FOXP3. In order to test whether RORC2 has the capacity to 
suppress FOXP3 expression, RORC2 was cloned as a fulllength construct (RORC2FL) as 
well as a truncated version lacking the DNA binding domain (RORC2ΔDBD), which was 
used as negative control. Naïve CD4+ T cells were transfected with these plasmids and 
Western blot analysis was performed to confirm recombinant expression of the proteins (Fig. 
17A). The molecular weight of the proteins observed on the gel were in accordance with the 
calculated molecular weight of app. 56 kDa for RORC2FL and 48 kDa for RORC2ΔDBD. 
The additional faint band at app. 50 kDa was due to unspecific binding of the antibody. To 
test the influence of RORC2 on FOXP3 expression, transfected T cells were stimulated with 
anti-CD3 and anti-CD28 antibodies in the presence of IL-2 and TGF-β and FOXP3 levels 
were determined by RT-PCR (Fig. 17B). In cells transfected with RORC2FL, FOXP3 mRNA 
levels decreased about 60 percent and (66±23% after 48 h and 61±14% after 5 d). For control, 
in cells transfected with the DNA-binding deficient RORC2ΔDBD mutant, FOXP3 levels 
were comparable to mock transfected cells. To investigate whether RORC2 can change 
FOXP3 protein levels, cells transfected with the RORC2 constructs were analyzed by flow 
cytometry after 5 d (Fig. 17C). Consistent with the results obtained by RT-PCR, RORC2FL-
transfected cells showed a markedly decreased FOXP3 staining (14.0±3.2%) compared to 
mock (22.0±1.9%) or RORC2ΔDBD transfected cells (23.2±1.8%). Taken together, these 
results demonstrate an inhibitory role for RORC2 on FOXP3 mRNA and protein expression 
by a DNA binding-dependent mechanism. 
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Fig 17. Over-expression of RORC2 inhibits FOXP3 expression. A, Naïve CD4+ T cells were transfected with 
RORC2ΔDBD and RORC2FL and expression of the proteins was analyzed by Western blot. B and C, Naïve 
CD4+ T cells were transfected with RORC2FL and RORC2ΔDBD. 8 h after transfection the cells were 
stimulated with anti-CD3 and anti-CD28 antibodies in the presence of IL-2 and TGF-β. B, FOXP3 mRNA levels 
were determined by RT-PCR after 48 h and 5 d and levels in untreated cells were set to 100%. C, FOXP3 protein 
expression was measured by FACS after 5 days. Bars/numbers indicate mean and standard deviation of at least 3 
independent experiments. 
 
 
Knockdown of RORC2 increases FOXP3 levels 
The observation that high RORC2 levels result in a down-regulation of FOXP3 led us to the 
hypothesis that a decrease in RORC2 might enhance the expression of FOXP3. To test this, 
RORC2 was knocked-down using siRNA oligonucleotides. Two different oligonucleotides 
were tested and a dose-titration as well as a time-kinetic was performed to validate RORC2 
knockdown (Fig. 16). Cells were transfected with siRNA against RORC2 or with a scrambled 
siRNA as negative control and then cultured with anti-CD3 and anti-CD28 antibodies in the 
presence of IL-2 and TGF-β. After 48 h, mRNA levels of RORC2 and FOXP3 were 
determined by RT-PCR (Fig. 18A). In cells transfected with siRNA against RORC2, levels of 
RORC2 were knocked-down by 76.1±14% compared to untransfected cells, while no effect 
was observed with scrambled siRNA, confirming the specificity of the assay. In cells with 
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reduced RORC2 levels due to siRNA treatment, a 3-fold increase in FOXP3 was observed. To 
analyze FOXP3 expression on protein level, cells were cultured for 5 d under the same 
conditions and then subjected to FACS analysis (Fig. 18B). Consistent with the results 
obtained by RT-PCR, numbers of FOXP3 positive cells increased in the presence of siRNA 
against RORC2 compared to scrambled siRNA-transfected cells (from 20.1±2.0% to 
28.5±4.0%). These data reveal that down-regulation of RORC2 increases FOXP3 expression 
and they are in agreement with the results above showing reduced FOXP3 expression after 
RORC2 over-expression. 
 
 
                            
 
Fig 18. SiRNA-mediated knockdown of RORC2 increases FOXP3 expression. Naïve CD4+ T cells were 
transfected with siRNA oligonucleotides targeting RORC2. 8 h after transfection the cells were stimulated with 
anti-CD3, anti-CD28 antibodies in the presence of IL-2 and TGF-β. mRNA levels of RORC2 (left) and FOXP3 
(right) were determined by RT-PCR after 48 h and 5 d (A). Levels in untreated cells were set to 100% or to 1, 
respectively. Bars represent mean and standard deviation of at least 3 independent experiments. FOXP3 protein 
expression was measured by FACS after 5 d (B). Numbers indicate mean and standard deviation of at least 3 
independent experiments. 
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RORC2 binds to the FOXP3 promoter at RORE -942 and RORE +115 
Transcription factors of the nuclear receptor family like RORC2 control gene expression by 
binding to the promoter of their target genes. To investigate the mechanism by which RORC2 
controls FOXP3 expression, we first analyzed the FOXP3 promoter sequence for the presence 
of ROREs, putative binding sites for RORC2 (Fig. 19A). The sequence from bp -1242 until 
bp +223 contains four ROREs, three upstream (at -1096, -942 and -847) and one downstream 
the transcription start site (at +115). These putative binding sites for ROR-family members 
are conserved among the FOXP3 promoters of different species (Fig. 19B). Direct binding of 
RORC2 to the FOXP3 promoter was assessed using a FOXP3 promoter ELISA system (Fig. 
20A). In this assay, either consensus sequences of 30 bp containing one RORE or promoter 
fragments spanning bp -1116 to +177 were coated on ELISA plates. Plates were incubated 
with extracts of HEK cells transfected with RORC2 or an empty vector as a control and 
binding of RORC2 was quantified by chemiluminescence following incubation with the 
appropriate antibodies. Binding of RORC2 to the wildtype, but not to the mutated consensus 
sequence was observed, validating the specificity of the assay. Absorbance was even slightly 
higher when extracts of HEK cells transfected with RORC2 were incubated with the FOXP3 
promoter sequence, while incubation with extracts from empty-vector-transfected cells 
produced only background levels of absorbance. These results suggest that RORC2 binds to 
one or more of the RORE on the FOXP3 promoter. The sequence specificity of the binding 
was further confirmed by addition of soluble oligonucleotides, which abolished binding by 
competition when they contained the wild type, but not a mutated consensus sequence. 
To investigate which of the four ROREs are important for binding of RORC2 to the FOXP3 
promoter, serial deletions of the FOXP3 promoter were constructed and fragments were 
coated on an ELISA plate (Fig. 20B). Binding of RORC2 to the promoter fragment lacking 
RORE-1096 was equal to binding observed using the fragment containing all four ROREs. 
However, when RORC2 was incubated with a construct lacking RORE-942, a drop in 
absorbance was detected, suggesting that RORE-942 is relevant for binding of RORC2 to the 
promoter. Deletion of RORE-847 did not substantially alter the absorbance of the promoter 
ELISA, while a clear drop in absorbance was found in the fragment lacking also RORE+115. 
RORC2 has been described to compete with NFAT for DNA binding (229). As three putative 
NFAT binding sites are located on the FOXP3 promoter (Fig. 19A), a construct lacking these 
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sites was analyzed for RORC2 binding (Fig. 20B). However, no difference in binding was 
observed.  
 
           
 
Fig 19. The FOXP3 promoter contains conserved ROREs. A, Sequence of the FOXP3 promoter from bp -
1246 to bp +223. ROREs are marked in blue, NFAT binding sites are marked in green. CAAT, GC and TATA 
boxes are indicated with orange boxes. Primers used for generation of the promoter fragments are marked with 
black arrows, TSS = transcription start site. B, FOXP3 promoters of different species were aligned using the 
genomatix software. Conserved bases are highlighted in bold, RORE core sequences are marked with blue 
boxes. 
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Fig 20. RORC2 binds to the FOXP3 promoter. A, Nuclear extracts of HEK cells transfected with either 
RORC2 or an empty vector were incubated with a wildtype or a mutated RORE consensus sequence or with the 
FOXP3 promoter in the presence or absense of competitor oligonucleotides. Binding of RORC2 was quantified 
using the FOXP3 promoter ELISA assay. Bars show mean and standard deviations of triplicates representative 
of three independent experiments. B, Nuclear extracts of HEK cells transfected with RORC2 were incubated 
with FOXP3 promoter fragments of different length. Binding of RORC2 was quantified using the FOXP3 
promoter ELISA assay. Bars show mean and standard deviations of triplicates representative of three 
independent experiments. C, Naïve CD4+ T cells were co-transfected as indicated. 8 h after transfection the cells 
were stimulated with anti-CD3, anti-CD28 antibodies for 12 h until luciferase activity was measured. Bars 
represent mean and standard deviation of 3 independent experiments. (wt = wildtype, mut = mutated) 
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To find out whether binding to the FOXP3 promoter is required for RORC2-mediated 
inhibition, a FOXP3 promoter luciferase assay was performed (Fig 20C). Co-transfection of 
RORC2FL and a luciferase plasmid containing the FOXP3 promoter resulted in a 67% 
reduced luciferase activity compared to the luciferase activity in cells transfected with the 
luciferase vector and an empty vector (26.4±17 fold versus 79.3±13 fold increase to the basic 
luciferase plasmid). In contrast, co-transfection with RORC2ΔDBD generated a luciferase 
activity comparable to empty vector co-transfection. Taken together, these results suggest that 
RORC2 inhibits FOXP3 expression by binding to its promoter at RORE-942 and RORE+115. 
 
Knockdown of RORC2 shifts Th17 cells towards T cells with a less pro-inflammatory but 
more regulatory phenotype 
To investigate whether these findings have an implication in T cell differentiation - especially 
in the balance between Treg and Th17 cells - we analyzed whether lack of RORC2 shifts 
Th17 cells towards a Treg phenotype. Therefore, RORC2 was down regulated in naïve T cells 
using siRNA and the cells were cultured under either Treg or Th17 differentiation conditions. 
As expected, in control settings (i.e. scrambled siRNA-transfected cells) FOXP3 mRNA 
levels were clearly higher in Treg than in Th17 (Fig 21A). However, in Th17 cells with down-
regulated RORC2 levels, FOXP3 expression was significantly increased, almost reaching 
levels in siRNA treated Treg cells. Similarly, frequencies of FOXP3 positive cells in siRNA 
transfected Th17 cells were comparable to frequencies in cells cultured under Treg 
conditions, while in cells transfected with control siRNA a considerably smaller fraction of 
Th17 cells was FOXP3 positive (Fig 21B). We further analyzed the cytokine profile of Th17 
cells carrying reduced RORC2 levels during differentiation due to siRNA treatment (Fig 
21C). As expected and previously reported (162, 163), IL-17A levels were markedly reduced 
in these cells. Moreover, these cells also showed a decreased expression of other pro-
inflammatory cytokines like IL-1β, IL-6, IFN-γ and TNF-α (Fig 21C left), while no changes 
in IL-5 and IL-13 levels were observed (Fig 21C right), suggesting a specific effect. These 
results indicate that Th17 cell development is impaired in RORC2-depleted cells and that 
these cells instead differentiate towards a less pro-inflammatory but more tolerating subset. 
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Fig 21. Down-regulation of RORC2 shifts Th17 cells towards less inflammatory phenotype. Naïve CD4+ T 
cells were transfected with siRNA against RORC2. 8 h after transfection the cells were cultured under Treg or 
Th17 conditions for 5 d. A, After 6 h of restimulation with anti-CD3, anti-CD28 antibodies, FOXP3 mRNA 
levels were measured by RT-PCR. Levels in scrambled siRNA transfected Treg cells were set to 1. Bars 
represent mean and standard deviation of 3 independent experiments. B, After 6 h of restimulation with PMA 
and Ionomycin, FOXP3 expression was analyzed by FACS. Numbers indicate mean and standard deviation of 3 
independent experiments. C, After 48 h of restimulation with anti-CD3 and anti-CD28 antibodies cytokine 
concentration was analyzed by Cytometric bead array. Bars represent standard errors of duplicates. Data shown 
are representative of 5 independent experiments. (siScram = scrambled siRNA) 
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Discussion 
 
The current study demonstrates repression of FOXP3 by the Th17 cell-promoting 
transcription factor RORC2 and thus identifies a novel role for RORC2 in T cell polarization.  
Over-expression of RORC2 decreased the levels of FOXP3 on both mRNA and protein level. 
This relationship was confirmed by siRNA-mediated knockdown of RORC2, which increased 
FOXP3 expression, indicating an inverse correlation of the two factors. Binding to the 
promoter of FOXP3 is necessary for RORC2-mediated repression, as overexpression of 
RORC2 lacking the DNA-binding domain did not inhibit FOXP3 expression. Moreover, no 
decrease in luciferase activity was observed upon co-transfection with the DBD-deficient 
construct. To further investigate the mechanism of repression, we analyzed the FOXP3 
promoter sequence from bp -1242 until bp +223 and identified four putative RORC2-binding 
sites. In agreement with the fact that ROR transcription factors bind DNA as monomers  (169, 
171, 173), all ROREs identified consist of a single independent motif. Three of these ROREs 
are located in a poorly characterized part of the FOXP3 gene, slightly upstream of the core 
promoter and the region, which we previously identified as an inductive area for TCR-
inducible signals such as NFAT and AP-1 (74, 230)(74, 230). A fourth RORE is situated 
downstream the transcription start site. Using an ELISA-based system, we detected binding of 
RORC2 to RORE-942 and to a lesser extend to RORE+115. ROREs consist of the DNA 
sequence GGTCA as a core motive and are often preceded by an A/T-rich sequence (171, 
172). This A/T-rich sequence of RORC2 binding sites is also found upstream of RORE-942. 
Altogether, these experiments reveal that repression of FOXP3 by RORC2 involves physical 
binding of RORC2 to two ROREs on its promoter, a mechanism commonly observed for 
ROR-family members. 
ROR-family transcription factors induce repression of target genes by recruiting co-
repressors, which induce chromatin de-acetylation and therefore gene repression (183-185). 
Several co-repressors have been described to interact with ROR family members and it 
remains to be determined, which of them mediates the repression of the foxp3 gene observed 
in this study. Retinoic acid has been reported to be a key factor in regulating the balance of 
Treg versus Th17 cells (86-88, 231). Although retinoic acid seems to mediate these effects by 
its cognate receptor retinoic acid receptor (RAR) α (89, 232), the mechanism possibly also 
involves RORC2, as retinoic acid has been found to bind to RORC2 and to inhibit its 
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transcriptional activity (178). Therefore, retinoic acid might favor Treg cell development by 
binding and inhibiting RORC2, leading to an increased FOXP3 expression. However, 
addition of retinoic acid did not change extract binding properties to the ROREs on the 
FOXP3 promoter (data not shown).  
Beside co-repressor-mediated suppression, RORC2 might also inhibit FOXP3 expression by 
competition with NFAT, which is important for TCR-induced foxp3 gene activation (74), as 
RORC2 has been shown to bind to NFAT binding sites and to inhibit its transcriptional 
activity (229). In context of the foxp3 gene, we did not find binding of RORC2 to NFAT 
binding sites, suggesting an alternate mechanism of repression. Since IL-2 plays a major role 
in FOXP3 induction (76, 77) and RORC2 has been shown to suppress IL-2 production  (170), 
it may exert its inhibitory function through negative regulation of autocrine IL-2 secretion. In 
fact, levels of IL-2 dropped significantly upon siRNA-mediated RORC2 knockdown (data not 
shown).  
The siRNA-induced RORC2-knockdown during differentiation of Th17 cells led to a 
phenotype characterized not only by high FOXP3 expression, but also by low levels of pro-
inflammatory Th17 and Th1 cytokines such as IL-1β, IL-6 and IL-17A as well as IFN-γ and 
TNF-α, respectively. This suggests an important role for RORC2 in the inhibition of Treg 
development under inflammatory conditions. Reduced levels of IL-17A are presumably a 
direct consequence of RORC2 knockdown, which is known to regulate IL-17A expression on 
a transcriptional level (167). In contrast, the decrease in IFN-γ is a novel observation and 
might be caused indirectly by the increased FOXP3 expression, as FOXP3 has been shown to 
repress IFN-γ production (233).  
Crossover inhibition of T cell subsets during differentiation is an important mechanism to 
ensure polarization and clonal expansion of the most efficient subset. The presented data 
highlight a new role for the Th17 cell master regulator RORC2 in the inhibition of the Treg-
specific transcription factor FOXP3, thereby revealing a new mechanism of Treg-Th17 cell 
cross-regulation. Both T cell subsets require TGF-β for their development, whereas Th17 
cells additionally need inflammatory cytokines (150-152, 162, 228). While the Th17 cell-
inducing cytokines IL-6, IL-21 and IL-23 favor RORC2 over FOXP3 expression (90-93, 227, 
234), IL-2, retinoic acid, as well as IL-27, which inhibits Th17 cells and enhances TGF-β-
induced FOXP3 expression (82, 235-237), might shift the balance towards FOXP3 expression 
and Treg cell development. Based on these findings and the results of our study, we propose a 
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model in which FOXP3-mediated inhibition of RORC2 dominates under non-inflammatory 
conditions, while inflammation favors RORC2 and suppression of FOXP3 by RORC2 (Fig. 
22).  
The current report demonstrates that RORC2 is involved in the polarization of T cells by 
negative regulation of FOXP3 and therefore reveals an important pathway for future 
developments of drugs acting on the delicate balance between immunity and tolerance. 
 
 
 
   
 
 
 
Fig 22. Mutual regulation of the transcription factors FOXP3 and RORC2. TGF-β induces both FOXP3 and 
RORC2. Under non-inflammatory conditions, mediators like IL-2, retinoic acid (RA) or IL-27 enhance TGF-β-
induced FOXP3 expression. FOXP3 inhibits DNA-binding of RORC2 and thereby its transcriptional activity 
through physical interaction. As FOXP3 levels predominate under these conditions, no active RORC2 is 
available to repress the foxp3 gene and to activate Th17 cell programs. FOXP3 levels further increase, promoting 
the development of Treg cells. During inflammation, Th17-differentiating cytokines such as IL-6, IL-21 and IL-
23 enhance RORC2 expression and/or inhibit FOXP3 expression, thereby favoring RORC2 over FOXP3. 
RORC2 further inhibits FOXP3 expression and induces transcriptional programs leading to Th17 cell 
development. 
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2.3 Statement of contribution to publications 
 
I have performed all the experiments for both publications except for the suppression assay, 
which was performed by Nadia Ouaked. For the publication entitled “RORC2 is involved in T 
cell polarization through interaction with the FOXP3 promoter” I used the FOXP3 promoter 
in the pGL4 vector that has been previously cloned by Pierre-Yves Mantel. 
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3 DISCUSSION 
 
The differentiation of naïve T cells towards Th17 or Treg cells must be tightly controlled in 
order to establish equilibrium between protective immune responses and tolerance against 
harmless (self-) antigens. The current thesis demonstrates that when stimulated by TGF-β, IL-
1β, IL-6 and IL-23, naïve human T cell differentiate into Th17 cells, a population that 
potently induces pro-inflammatory mediators in bronchial epithelial cells. Over-expression 
and knockdown experiments revealed that RORC2 plays a decisive role in T cell 
differentiation by negative regulation of the foxp3 gene, thereby favoring Th17 over Treg cell 
development. 
 
 
3.1 Requirements for Th17 cell differentiation 
 
While there is consent about the mediators inducing differentiation of murine Th17 cells, the 
factors required for human Th17 development are controversially discussed. The present 
thesis demonstrates that TGF-β, the pro-inflammatory cytokines IL-1β and IL-6, as well as 
IL-23 are required for the development of a functional Th17 effector population, 
characterized by high production of IL-17A and IL-17F.  
While other T cell subsets depend on IL-2 for their survival, Th17 cells seem to be rather 
inhibited by IL-2, at least in mice (157). In agreement with these observations, Th17 cell 
development was not further enhanced by IL-2, but we did not observe an inhibition of Th17 
cells development, neither. IL-21, a common gamma chain family member like IL-2, has been 
suggested to act as a survival factor for Th17 cells and may even substitute for IL-6 (92, 154, 
158). Consistently, we noticed a slight IL-17A induction by TGF-β and IL-21. However, the 
addition of IL-21 to the cytokine cocktail TGF-β, IL-1β, IL-6 and IL-23 did not lead to a 
further enhancement of IL-17A and IL-17F. As IL-21 is induced by IL-6 and produced by 
Th17 cells themselves (92), it is likely that the cells cultured with TGF-β, IL-1β, IL-6 and/or 
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IL-23 secrete substantial levels of IL-21, which then acts in an autocrine manner, overcoming 
an effect of supplemental IL-21.  
The necessity for TGF-β in the development of human Th17 cells is currently under debate. 
In serum-free conditions we found a crucial role for TGF-β in the induction of Th17-specific 
genes IL-17A, IL-17F and RORC2. The discrepancies between different studies might be due 
to differences in culture conditions such as usage of serum. It is assumed that an appropriate 
concentration of TGF-β is crucial for Th17 cell differentiation and that high doses of TGF-β 
rather suppress IL-17, as observed for other cytokines. Therefore, low levels of TGF-β 
present in serum might be sufficient for Th17 cell differentiation and the concentration might 
exceed the optimum upon additional TGF-β supplementation. Furthermore, TGF-β is possibly 
required at early stages of Th17 development, but at later stages it rather inhibits IL-17 
production. This hypothesis is supported by our observation showing that neutralizing anti-
TGF-β antibodies decrease IL-17 production in naïve T cells cultured under Th17 conditions, 
whereas these antibodies do not affect IL-17 production in memory cells. Consistent with 
these results, previous studies suggest that TGF-β is not required for IL-17 induction in 
memory cells and that an optimal induction of IL-17 production requires cell-cell contact with 
activated monocytes (223). Our study therefore reveals similarities and differences between 
mice and human regarding differentiation of Th17 cells. 
 
 
3.2 Th17 cell effector mechanisms 
 
Th17 cells seem to contribute to inflammation in several diseases through secretion of 
cytokines that induce pro-inflammatory mediators in cells of the affected tissues. In 
agreement with this, we found that in vitro-differentiated Th17 cells potently induce 
production of the pro-inflammatory cytokines IL-6 and IL-1β in primary bronchial epithelial 
cells. In addition, we observed up-regulation of G-CSF, GM-CSF and IL-8 production, 
consistent with their role in granulopoiesis and attraction of neutrophils (143, 218).  To a 
certain extent, induction of these mediators was also observed in epithelial cells co-cultured 
with other T helper cell subsets, especially with Th1 cells. However, the effect was much less 
pronounced compared to Th17 cells. These results clearly show that in vitro-differentiated 
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Th17 cells differ from other T cell subsets in their potency to induce pro-inflammatory 
cytokines. 
Th17 cells induced higher levels of IL-6 than equal amounts of recombinant IL-17A. 
Furthermore, the induction of IL-6 by Th17 cells was not fully abrogated by anti-IL-17A 
antibodies. Therefore, we speculate that other cytokines secreted by Th17 cells, such as IL-6, 
IL-22, IL-26, IL-17F or TNF-α (92, 96-99), synergize with IL-17A in the induction of pro-
inflammatory cytokines in epithelial cells. Furthermore, the heterodimeric cytokine formed by 
IL-17A and IL-17F might be of relevance, as it has been shown to induce airway neutrophilia 
in mice (238).  
IL-6 production by bronchial epithelial cells also substantially increased when the cells were 
stimulated with cell-free supernatants of Th17 cell cultures, suggesting that cell-cell contacts 
are not necessary for the induction of IL-6. Th17 cells produce more IL-17A when co-
cultured with bronchial epithelial cells, indicating that Th17 cells promote the differentiation 
and expansion of their own population through induction of pro-inflammatory cytokines like 
IL-6 and IL-1β. Such a positive feedback mechanism is observed for other T helper cell 
subsets as well. 
Elevated levels of both IL-6 and IL-17A have been found in plasma and airways of asthmatic 
individuals (213, 217). Our data showing that in vitro-differentiated Th17 cells potently 
induce IL-6 production by primary bronchial epithelial cells provide a further link between 
these cytokines and are a hint that Th17 cells contribute to airway inflammation in severe 
asthma. Through induction of neutrophil-attracting factors such as G-CSF, GM-CSF and IL-
8, they might also play an important role in airway neutrophilia during allergic airway 
inflammation.  
Taken together, our results show that human Th17 cells potently induce pro-inflammatory and 
chemoattracting mediators in primary bronchial epithelial cells and therefore indicate a role 
for Th17 cells in allergic asthma. 
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3.3 Expression of the transcription factor RORC2  
 
The transcription factor RORC2 has been shown to play a key role in Th17 differentiation 
(162, 163), as RORC2-deficient mice show markedly reduced numbers of Th17 cells. 
Consistently, we found high levels of RORC2 in Th17 cells and substantially decreased IL-17 
secretion after siRNA-mediated knockdown of RORC2. We also observed high levels of 
RORC2 in CD8+ cells, which were reported to express IL-17A (220, 221). Two very recent 
reports confirm our finding of RORC2 expression in these cells (239, 240). Interestingly, we 
found high RORC2 levels also in NKT cells, consistent with a study reporting their IL-17 
expression (222). In the course of this thesis, RORC2 has been described to play an important 
role in the development of an IL-17-producing subset of invariant NKT cells (241). 
Surprisingly, we detected RORC2 to be expressed also in TGF-β-induced Treg cells, as well 
as in naturally occurring CD25+ Treg cells, which did not produce IL-17A. This suggests that 
RORC2 expression does not necessarily imply IL-17A production. IL-17A expression in Treg 
cells might be suppressed by FOXP3, which we detected only in Treg, but not in Th17 cells. 
Such a repression has been suggested by two reports showing that in mice Foxp3 inhibits 
RORC2 function through direct interaction (14, 15).  
Taken together, our findings indicate that RORC2, despite its crucial role in Th17 
development, is not a selective marker for IL-17-producing T helper cells. Investigation of 
Th17 cells therefore requires analysis of other characteristic genes like for example their 
hallmark cytokines IL-17A and IL-17F. 
 
 
3.4 Regulation of the foxp3 gene by RORC2 
 
During T cell differentiation, an individual T cell subset promotes not only its own 
development and expansion, it also inhibits differentiation of other subsets. Mutual inhibition 
of T cell subsets, which is an important mechanism of T cell polarization, is partially 
mediated by cytokines, but also by the lineages specific transcription factors. T-bet, the 
transcription factor of Th1 cells, has been shown to inhibit Th2 development (10), while 
DISCUSSION 
   
 - 76 - 
GATA-3 suppresses both Th1 and Treg cells differentiation (12, 13). FOXP3 inhibits 
transcriptional activity of RORC2, thereby limiting Th17 development (14, 15). In this thesis, 
we demonstrate that RORC2 is involved in T cell cross-regulation. Over-expression of 
RORC2 in naïve T cells led to a decreased expression of FOXP3 on both mRNA and protein 
level. Conversely, siRNA-mediated knockdown of RORC2 enhanced FOXP3 expression. The 
inverse correlation of the transcription factors suggests that the Th17 cell master regulator 
RORC2 negatively regulates expression of the Treg-specific transcription factor FOXP3. 
Physical interaction of RORC2 with the foxp3 gene is necessary for RORC2-mediated 
repression, as overexpression of RORC2 lacking the DNA-binding domain did not inhibit 
FOXP3 expression. Moreover, no decrease in luciferase activity was observed upon co-
transfection with the DBD-deficient mutant of RORC2. This is in agreement with the fact that 
DNA-binding dependent mechanisms of repression are commonly observed for ROR-family 
transcription factors. 
These data reveal a novel function for RORC2 in T cell polarization. It remains to be 
determined whether RORC2 also influence the transcription factors of Th1 and Th2 cells and 
therefore represents a universal regulator of polarization.  
 
 
3.5 RORC2 binding motifs in the FOXP3 promoter 
 
Nuclear receptor family transcription factors mediate transcriptional activation or repression 
by binding to specific DNA motives in the regulatory region of their target genes. The 
consensus DNA binding elements for ROR-family members are ROREs. They consist of the 
DNA sequence GGTCA as a core motive, which is often preceded by an A/T-rich sequence 
(171, 172). In contrast to other nuclear receptors, members of the ROR-family transcription 
factors bind DNA as monomers. Therefore, their cognate DNA binding sites exist as single 
motives instead of palindromic sequences. We identified four putative binding sites for ROR 
family transcription factors in the FOXP3 promoter sequence from bp -1242 until bp +223, all 
consisting of single independent motives. Three of these ROREs are located in a poorly 
characterized part of the FOXP3 gene, slightly upstream of the core promoter and the region, 
which we previously identified as an inductive area for TCR-inducible transcription factors, 
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such as NFAT and AP-1. A fourth RORE is situated downstream the transcription start site. 
RORC2 was observed to bind to RORE-942 and to a lesser extend to RORE+115. Consistent 
with its importance in RORC2 binding, an A/T-rich sequence is found upstream of RORE-
942. Also RORE-1096, to which we did not observe binding of RORC2, is adjacent to such a 
sequence. However, RORE-1096 is inverted, which might be a hint that it does not take part 
in RORC2-mediated inhibition and is therefore not interacting with RORC2. In contrast, no 
A/T-rich sequence is found upstream to RORE-847, consistent with our finding that it is not 
bound by RORC2. As gene regulation can take place in regions more distant from the 
transcription start site, it is likely that further ROREs exist, which were not analyzed in this 
study. Moreover, it remains to be determined, which of the ROREs that we found to interact 
with RORC2 are important for inhibition of the foxp3 gene. Altogether, these experiments 
reveal that negative regulation of FOXP3 by RORC2 involves physical binding of RORC2 to 
two ROREs on its promoter, a mechanism commonly observed for ROR-family members. 
 
 
3.6 Mechanisms of RORC2-mediated FOXP3 suppression 
 
Transcription factors of the ROR-family exert their repressive function through interaction 
with co-repressors. However, very little is known about the mechanisms of RORC2-mediated 
gene repression. Likewise, the co-repressors with which RORC2 interacts to exert the 
negative regulation of the foxp3 gene observed in this study still remain to be determined.  
RORC2 has been shown to compete with NFAT for DNA binding, which leads to an 
inhibition of NFAT-induced gene transcription (229). As NFAT is important for TCR-
induced activation of the foxp3 gene (74), RORC2 might inhibit FOXP3 expression by 
competition with NFAT for its binding sites on the promoter, rather than through interaction 
with a co-repressor. However, in our experiments, we did not observe binding of RORC2 to 
NFAT binding sites in the FOXP3 promoter, which suggests that in the case of FOXP3, a 
different mechanism of inhibition takes place.  
RORC2 has been reported to suppress IL-2 production (170). Consistent with this report, we 
observe an increased production of IL-2 in cells treated with siRNA against RORC2. IL-2 
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plays an important role in the development of Treg cells and in the induction of FOXP3 (76, 
77). Therefore, RORC2 might inhibit FOXP3 expression by depriving the cells of IL-2.  
Taken together, several mechanisms of RORC2-mediated FOXP3 suppression are possible 
and further experiments are needed to elucidate the molecular basis of the inhibition. 
 
 
3.7 Mechanisms regulating the balance of Treg and Th17 cell 
differentiation 
 
Treg and Th17 cells both depend on TGF-β for their development, while Th17 cells 
additionally require a pro-inflammatory environment (150-152, 162, 228). Based on these 
data and on our results, we like to suggest a model in which FOXP3-mediated inhibition of 
Th17 cells dominates under silent conditions, while FOXP3 expression is suppressed by 
RORC2 during inflammation, allowing the development of Th17 cells (Fig. 23). In this 
model, the differentiation of Treg versus Th17 cell is constantly balanced. The Th17 cell-
inducing cytokines IL-6, IL-21 and IL-23 favor RORC2 over FOXP3 expression (90-92, 227, 
234). The cytokine IL-27, in contrast, seems to favor the development Treg cells, as one of 
our previous studies showed that IL-27 enhances TGF-β-induced FOXP3 expression in a 
STAT1-dependent manner (82). Furthermore, IL-27 has been reported to inhibit development 
of Th17 cells (235-237). Retinoic acid is a key factor in regulating the balance of Treg versus 
Th17 cells (86-88, 231). It exerts its functions by binding to and thereby activating the 
retinoic acid receptor (RAR) α, its cognate receptor (89, 232). However, the mechanism of 
RA-mediated inhibition of Th17 cells might also involve RORC2, which is structurally 
closely related to RARα. Indeed, retinoic acid has been described to act as a ligand for 
RORC2, thereby inhibiting its transcriptional activity (178). Retinoic acid might therefore 
favor Treg cell development by binding and inhibiting RORC2, leading to an increased 
FOXP3 expression. However, in our study, addition of retinoic acid did not change extract-
binding properties to the ROREs on the FOXP3 promoter, arguing for a different role for 
retinoic acid in the Treg-Th17 cell balance. 
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Fig 23. Factors regulating the Treg-Th17 cell balance. Under normal condition, IL-2, retinoic acid (RA) and 
IL-27 support FOXP3-mediated RORC2 inhibition, whereas inflammatory cytokines promote suppression of 
FOXP3 by RORC2 during inflammation. These mechanisms lead to the dominance of Treg cells and thereby to 
tolerance under silent condition, while ensuring predominance of Th17 cells during infection. 
 
 
 
3.8 Phenotype shift upon RORC2 downregulation 
 
Knockdown of RORC2 using siRNA increased FOXP3 level not only in a Treg-favoring 
environment, but induced comparably high levels of FOXP3 also in cells differentiated under 
Th17 conditions. These cells develop a phenotype characterized by high FOXP3 expression 
and low levels of pro-inflammatory cytokines. As previously reported (162, 163), IL-17A 
production was markedly reduced in Th17 cells that underwent siRNA-mediated RORC2 
knockdown. Furthermore, we observed a reduction of other Th17 cell-related cytokines like 
IL-1β and IL-6. Interestingly, also the levels of IFN-γ and TNF-α, cytokines generally 
associated with Th1 cells, were lower in siRNA-treated cells, while the Th2 cytokines IL-5 
and IL-13 remained unchanged. Knockdown of RORC2 therefore induces a downregulation 
of cytokines mediating inflammation.  
Reduction of IL-17A expression is presumably a direct consequence of a lack of RORC2, as 
IL-17A expression is regulated by RORC2 on transcriptional level (167). The decrease in 
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IFN-γ after RORC2 knockdown, however, might be caused rather indirectly through 
increased FOXP3 expression, as FOXP3 has been shown to repress IFN-γ production (233). 
The fact that down-regulation of RORC2 shifts T cells from a pro-inflammatory towards a 
Treg like cell suggests RORC2 to be a target for therapies aiming to modify the inflammatory 
nature of an immune response and to induce tolerance. 
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3.9 Conclusion  
 
This thesis investigated development and function of human Th17 cells and analyzed mutual 
cross-regulation of Th17 and Treg cells during T cell differentiation. We identified mediators 
inducing development of naïve human T cells into Th17 cells and showed that these cells 
significantly differ from other T helper cells in their potency to induce secretion of pro-
inflammatory cytokines in primary bronchial epithelial cells. Furthermore, we revealed a role 
for RORC2 in T cell polarization through interaction with the FOXP3 promoter. T cells with 
down-regulated levels of RORC2 develop a Treg-like phenotype even under Th17-favoring 
conditions, suggesting that the role of RORC2 in Th17 cell development involves not only 
induction of Th17-characteristic genes, but also suppression of Treg-specific programs. 
 
The current thesis reveals novel mechanisms of T cell polarization of subsets with opposed 
functions and thereby gives insight into the regulation of immunity and tolerance. These 
mechanisms are of considerable interest, as disruption of the balance between immunity and 
tolerance can lead to insufficient immune responses or inflammatory diseases. Our results 
therefore build a basis for the elaboration of therapies aiming to restore the balance between 
tolerance and immunity and suggest RORC2 to be a target for anti-inflammatory drugs. 
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